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ABSTRACT: With the emergence of multidrug-resistant
strains of Mycobacterium tuberculosis there is a pressing need
for new oral drugs with novel mechanisms of action. Herein,
we describe the identiﬁcation of a novel morpholino−
thiophenes (MOT) series following phenotypic screening of
the Eli Lilly corporate library against M. tuberculosis strain
H37Rv. The design, synthesis, and structure−activity relation-
ships of a range of analogues around the conﬁrmed actives are
described. Optimized leads with potent whole cell activity
against H37Rv, no cytotoxicity ﬂags, and in vivo eﬃcacy in an
acute murine model of infection are described. Mode-of-
action studies suggest that the novel scaﬀold targets QcrB, a subunit of the menaquinol cytochrome c oxidoreductase, part of the
bc1-aa3-type cytochrome c oxidase complex that is responsible for driving oxygen-dependent respiration.
■ INTRODUCTION
Mycobacterium tuberculosis (M. tuberculosis) is the causative
agent of tuberculosis (TB), an airborne transmitted disease
that is fatal if not properly treated. TB disproportionately
aﬀects developing countries and now outranks HIV as the
leading cause of death from an infection worldwide. In 2015,
1.8 million people died of TB (1.4 million HIV-negative and
0.4 million HIV positive).1 The current treatment regimen is
considered antiquated and inadequate, taking a minimum of 6
months to cure patients, which contributes to high default rates
leading to increased transmission, drug resistance, and even
death.2−4 As a consequence, new TB drugs working through
existing and novel mechanisms are urgently required.5,6
Although there has been increased investment in TB drug
discovery over the past 10 years this has remained a signiﬁcant
challenge, and high-quality novel chemical starting points are
still urgently required.7
Identiﬁcation of TB drug discovery starting points through
in vitro target-directed screens has been largely unsuccessful.6
As a result, cell-based phenotypic screening has emerged as a
preferred means to identify novel antitubercular scaﬀolds. In
this study a cluster of novel morpholino−thiophenes (MOT)
analogues was identiﬁed from the Lilly corporate screening
deck using an aerobic whole cell phenotypic screen of M.
tuberculosis strain H37Rv. The initial hit had good anti-
tubercular activity with a minimum inhibitory concentration
(MIC) of 0.72 ± 0.30 (n = 14). Resynthesis and proﬁling of
hits from the primary screen conﬁrmed antitubercular activity
with good potency and selectivity over both VERO and
HepG2 cytotoxicity counter screens (see Table 1 for an
example). The representative conﬁrmed hit 1 had good M.
tuberculosis MIC-derived metrics such as lipophilic ligand
eﬃciency,8 where LLEM. tuberculosis = pMIC − c log P or logD
and Property Forecast Index9 where PFI = no. of aromatic
rings + log P, suggesting that the series had potential to be
optimized into a high-quality oral drug candidate.10,11
Physiochemical properties such as MW, log P, log D, and
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TPSA were in an acceptable range for oral drugs.11,12 Kinetic
solubility suggested 1 was highly soluble, although later
additional solubility proﬁling of analogues found thermody-
namic solubility to be an issue. Compound 1 showed moderate
CYP inhibition and no in vitro hERG liability. The perceived
issue for 1 was metabolic stability as a result of high mouse
microsomal clearance, albeit human microsomal clearance was
moderate.
Related thiophene pharmacophores, where the morpholine
is replaced by a benzimidazole group, have been investigated
for other disease areas. Analogues with no ether chain and a
benzimidazole functionality have been reported as inhibitors of
Plasmodium falciparum dihydroorotate dehydrogenase.13 Ana-
logues with a benzimidazole functionality and an ether side
chain have been reported as polo-like kinase (PLK) and Never
in Mitosis Gene A-Related Kinase 2 (Nek2) inhibitors.14−17
The thiophene-2-carboxamide substructure has also been
observed within antitubercular inhibitor agents (Figure 1).
The structure of the thiophene 2 inhibitor of mycoyltransferase
bound to M. tuberculosis FbpC has been solved.18 Recently,
TCA1 3 has been reported to target both decaprenylphos-
phoryl-β-D-ribose oxidase (DprE1) and MoeW and was found
to have in vitro bactericidal activity against both replicating and
nonreplicating M. tuberculosis as well as being eﬃcacious in
both acute and chronic mouse models of TB infection.19
Herein, we report on the proﬁling of emerging leads from
the MOT series that suggested that they likely target QcrB, a
subunit of the menaquinol cytochrome c oxidoreductase (bc1
complex) that is part of the bc1-aa3-type cytochrome c oxidase
complex, driving oxygen-dependent respiration. The imidazo-
[1,2-a]pyridine-3-carboxamides have recently been shown to
target QcrB and are currently undergoing clinical develop-
ment.20−24 The proﬁle and novelty of representative conﬁrmed
hit 1 was considered promising, and a medicinal chemistry
program was established to derive a better understanding of
the pharmacophore based on structure−activity relationship
(SAR) studies.
■ CHEMISTRY
Synthetic Routes. Synthesis of the MOT scaﬀold was
initially achieved using the route outlined in Scheme 1. Amide
5 was formed by reaction of acyl chloride 4 with morpholine
and then converted to thioamide 6 following treatment with
Lawesson’s reagent. Thioamide 6 was reacted with 2-
aminoacetyl bromide to yield hydroxy-thiophene 7. Mitsuno-
bu25 or alkylation reactions yielded the desired thiophene 8.
However, a major drawback of this route was that 2-
substituted-5-morpholino-3-oxo-2, 3-dihydrothiophene-2-car-
boxamide 9 was the major product, regardless of whether the
Mitsunobu or alkylation reaction was employed to introduce
the ether chain.
To circumvent the issues with formation of 9, an alternative
route was developed that relied on the early introduction of the
ether side chain followed by introduction of the morpholine
(Scheme 2). Using methyl 3-hydroxythiophene-2-carboxylate
10 in the Mitsunobu ether formation aﬀorded phenyl ethyl
derivative 11. Regioselective iodination with LDA and iodine
aﬀorded the versatile iodo-intermediate 12. The ester func-
tional group of 12 was converted to the primary amide 13 by
reaction with calcium chloride and ammonia in methanol.26
Suzuki27 or Buchwald28 reactions aﬀorded a range of
derivatives in this position (for example, 32, 34, and 35).
Hydroxamic acid derivative 16 was prepared from intermediate
12 using a Buchwald-type reaction to form 14, followed by
reaction of the ester with a tetrahydropyran protected
hydroxylamine to aﬀord 15, which was treated with p-
toluenesulfonic acid to aﬀord 16. Treatment of intermediate
11 with LDA and DMF aﬀorded aldehyde 17, which was
reacted with a range of amines, such as morpholine to give 18.
■ RESULTS AND DISCUSSION
The initial SAR investigation focused on systematically probing
the pharmacophore to understand the impact of each
functional group on antibacterial activity. Deletion analogues
and nearest neighbors were examined as well as functionality
on the phenyl ring with an overall aim of identifying key
structural modiﬁcations that could be made to improve
microsomal stability.
Primary Amide SAR. Modiﬁcations to the primary amide
provided scope to improve MIC potency and mouse
microsomal stability (Table 2). Removal of the primary
amide 19 or replacement with an ester 14 resulted in a loss of
activity, indicating it may be involved in the binding mode of
the MOT scaﬀold with its target or uptake into M. tuberculosis.
The methyl ketone 20 was found to be equipotent with 1 but
had a negative impact on mouse microsomal clearance. The N-
methyl amide 21 showed similar activity but also had a
Table 1. In Vitro Proﬁle of a Selected MOT Conﬁrmed Hit
MIC (H37RvLP) 0.72 ± 0.30 (n = 14)
Vero cytotoxicity Vero > 100 μM
LLE 4.2
PFI 4
Measure CHI Log D 2
Kinetic solubility >250 μM
MW 332
Clog P/D 2.6/2.0
TPSA 65
Microsomal clearance Mouse = 19 mL·min−1·g−1
Human = 3.5 mL·min−1·g−1
CYP inhibition (M) 2D6 (5), 2C9 (5.1), 1A2 (<5), 2C19 (5.9)
Figure 1. Antitubercular agents with a thiophene-2-carboxamide
substructure.
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negative impact on the mouse microsomal stability. The ethyl
22 and triﬂuoroethyl 23 derivatives both led to a drop in
potency. There were signiﬁcant improvements in microsomal
stability for the N-cyclobutyl amide 24; however, it came with
a loss in antitubercular activity. Encouragingly, both the
Weinreb amide 25 and the hydroxamic acid 16 showed
improved microsomal stability together with a moderate MIC.
A mix and match approach between TCA1 compound 3 was
also explored; however, 26 was found to be inactive. Overall,
the SAR for the primary amide replacement suggested that the
carbonyl is important for antitubercular activity, and micro-
somal stability can be improved (Table 2).
Morpholine Side Chain SAR. Replacement of the
morpholine 1 with hydrogen 27 or piperidine 28 resulted in
a loss of activity. The morpholin-3-one 29 showed improved
microsomal stability; however, there was a >10-fold drop in
potency. Bridged morpholine 30 showed a >5-fold drop in
activity, whereas the methyl-substituted morpholine 31 lost
activity, signiﬁcant improvements in microsomal stability were
not observed. Increasing the ﬂexibility by opening up the
morpholine ring to give 32 resulted in loss of activity. In light
of the similarity to reported PLK inhibitors,14,15 heteroar-
omatic replacements were considered. The PLK-related
benzimidazole derivative 33 was inactive; however, the triazine
34 and 4-pyridyl 35 displayed good potency. The microsomal
stability was improved by extending the morpholine with a
methylene linker 18; however, no antibacterial activity was
observed for an array of amines (data not shown). Overall, the
SAR for the morpholine substituent suggested that there was
limited scope for improving potency and microsomal stability
(Table 3).
Phenyl Ring and Ethyl Ether Linker SAR. The SAR
around the phenyl ring and the ethyl linker was examined to
see if the mouse microsomal stability could be improved by
changing the substituents and physiochemical properties of the
phenyl ethyl ether (Table 4). The 4-methoxy 36 was
equipotent with 1 and also had improved microsomal stability,
presumably as a result of a blocking metabolism on the phenyl
ring. The 4-triﬂuoromethoxyphenyl 37 also aﬀorded improved
antibacterial activity and microsomal stability. The o-, m-, and
Scheme 1. General Synthesis of Morpholino−Thiophinesa
aReagents and conditions: (i) Morpholine, DCM, 0 °C to rt; (ii) Lawesson’s reagent, 100 °C; (iii) 2-Bromoacetamide, NaH, THF, 0 °C to rt; (iv)
DIAD, PPh3, phenylethylalcohol (R1OH), THF, rt.
Scheme 2. Alternative Synthesis of Morpholino−Thiophinesa
aReagents and conditions: (i) DIAD, PPh3, phenylethylalcohol, THF, rt; (ii) Iodine, LDA, THF, −78 °C; (iii) CaCl2, NH3, MeOH, 150 °C, μW;
(iv) Suzuki: Boronic acid, Cs2CO3, Pd(PPh3)4, DMF, 80 °C or Buchwald: Amine, Proline, CuI, K3PO4, DMSO, 80 °C, μW; (v) LDA, DMF, THF,
−78 °C; (vi) Amine, NaBH(OAc)3, CHCl3, rt; (vii) O-tetrahydropyran-2-yl hydroxylamine, LiHDMS, THF, −78 °C; (viii) p-toluenesulfonic acid
monohydrate, MeOH.
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p-substitution patterns of ﬂuoro (38, 39, and 40) and o- and
m-methoxy (41 and 42) groups were tolerated but did not
signiﬁcantly improve the overall properties of the molecule,
suggesting that p-substitution of the phenyl group is favored.
The 4-pyridyl 43 and p-cyanophenyl 44 derivatives lost
activity, suggesting that polarity was not tolerated in this
region. Saturated polar heterocyclic alkyl analogues were
prepared, 45, 46, and 47, while they signiﬁcantly improved
microsomal stability, they lost whole cell activity, supporting
the notion that polarity was not tolerated in this region. The
phenethyl linker was found to be important for potency;
shortening the chain to a methylene linker 48 resulted in loss
of activity. Replacement of the O-linker to aﬀord an n-propyl
49 was tolerated but with a drop oﬀ in potency. Introduction
of a gem-diﬂuoro group 50 as well as hydroxylation 51 on the
benzylic position of the ethyl chain, designed in an eﬀort to
block benzylic oxidation, resulted in a loss of activity.
Constraining the ethyl linker to aﬀord 52 and 53 gave
improved microsomal stability but had a detrimental eﬀect on
potency. The SAR for the phenyl ring and ethyl linker
suggested that there is scope in this region for improving
microsomal stability (Table 4).
Core Replacement SAR. Phenyl was investigated as a
bioisosteric thiophene replacement, employing two substitu-
tion patterns (Table 5). The 4-morpholino 54 showed low
whole cell activity, whereas the 5-morpholino 55 had moderate
whole cell activity as well as improved microsomal stability.
The m-ﬂuorophenyl derivative 56 showed similar activity to
55. Additional SAR for the phenyl bioisosteric replacement
was explored and is similar to the reported thiophene SAR
(data not shown). The pyridyl core bioisoster 57 showed
signiﬁcantly improved microsomal stability with similar
potency to 55. Overall, the SAR for the thiophene core and
its bioisoster replacements suggested that there is scope in this
region for improving microsomal stability while maintaining
whole cell activity (Table 5).
Summary of Pharmacokinetic (PK) Studies. Represen-
tative compounds 1, 55, 37, 46, and 25 were selected for
mouse pharmacokinetic proﬁling to understand the correlation
between in vitro microsomal turnover and in vivo clearance
(Table 6). Compounds 55, 37, and 46, with improved in vitro
microsomal stability, showed improved Cmax and AUC oral
exposures versus 1. However, there was an in vitro microsomal
versus in vivo clearance disconnect for 1, 55, 37, and 46 where
there is an overprediction of clearance. The phenyl bioisosteric
replacement 55 showed improved in vitro clearance as well as
in vivo exposure versus 1. However, it had a reduced MIC
potency. Similarly, the saturated polar heterocycle 46 showed
signiﬁcant improved bioavailability but no measurable MIC
activity. Overall 37 had the best activity and in vivo PK proﬁle
with a moderate volume of distribution and bioavailability.
Weinreb amide 25, despite having excellent in vitro micro-
somal stability, showed similar poor Cmax and AUC compared
to 1. To better understand the optimization parameters
required to improve the oral exposures for compounds with
improved in vitro microsomal stability, a rat hepatic portal vein
(HPV) PK study was undertaken on lead 37.
Rat HPV PK Study for 37. The fraction of drug absorbed
(Fa) from the gastrointestinal tract was low at 21% of the total
administered drug, suggesting that the poor oral exposure was
largely due to low solubility and/or metabolism in the gut wall
during absorption since the permeability was observed to be
rapid (see below). A 44% hepatic extraction ratio (ER),
determined by measuring blood samples from the HPV
(before ﬁrst pass metabolism) versus the cardiac vein (systemic
circulation), suggested that metabolic stability was also an
issue, Table 7.
To better deﬁne the optimization parameters for improving
oral exposure, the permeability and eﬄux of selected
compounds were evaluated in a cell permeability assay. In
addition, further solubility screens and metabolite identiﬁca-
tion studies were performed.
Madin Darby Canine Kidney (MDCK) Permeability
Assay. Compounds 1, 37, 18, 46, and 56 were tested in an
MDCK assay and found to show good permeability as well as
no likely P-glycoprotein (P-gp) eﬄux issues (Table 8). This
Table 2. Primary Amide SAR
ID log P/TPSA R1 MIC,
a μM (n) VEROb IC50, μM (n) Cli mouse,
c mL.min−1.g−1
1 2.6/65 CONH2 0.72 ± 0.30 (14) >100 (7) 19
19 3.7/22 H >20 (4) 68 ± 42 (2) 37
14 3.7/48 CO2Me >20 (4) >100 (4) 50
20 3.4/39 COMe 0.42 ± 0.19 (5) 84 ± 15 (2) 41
21 2.8/51 CONHMe 0.12 ± 0.052 (5) 91 ± 16 (3) 36
22 3.1/51 CONHEt 1.7 ± 0.42 (2) 56 (1) 50
23 3.6/51 CONHCH2CF3 3.4 ± 0.64 (2) >100 (1) 30
24 3.7/51 CONHcyclobutyl >20 (2) 24 (1) 0.5
25 2.6/51 CONMe(OMe) 1.8 ± 1.4 (10) 78 ± 32 (5) 0.5
16 2.0/71 CONHOH 3.5 ± 1.6 (2) 58 (1) 6
26 3.3/77 CONHCO2Et >20 (3) >100 (2) 1
aMinimum inhibitory concentration (MIC90) is the minimum concentration required to inhibit the growth of M. tuberculosis in liquid culture. Data
are the average ± standard deviation of a minimum of two independent experiments; numbers of experiments is given (n). bInhibitory
concentration (IC50) is the concentration required to inhibit growth of Vero cells by 50%. Data are the average ± standard deviation of a minimum
of two independent experiments; numbers of experiments is given (n). cIntrinsic clearance (Cli) using CD1 mouse liver microsomes
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was unsurprising considering the favorable MW, log P, low
hydrogen bond donor (HBD) count, and TPSA observed for
the examples in Tables 1−5. The good permeability data
would suggest that solubility-limited absorption was likely to
be an underlying optimization issue for the series, not reﬂected
in the kinetic solubility screen. It is known that the electron-
deﬁcient bivalent sulfur atoms in thiophenes have low-lying σ*
orbitals available for interaction with electron donors such as
oxygen. As such an intramolecular interaction between the
thiophene sulfur σ* orbital and the carbonyl is likely stabilizing
a planar conformation.29 Furthermore, primary amides, in
particular aromatic ones, eﬀectively generate two-dimensional
intermolecular hydrogen-bonded networks30 that can also have
a dramatic eﬀect on the thermodynamic solubility.
Solubility Screening. Considering the results of the HPV
and permeability studies, we selected a number of compounds
for additional solubility proﬁling. Compounds 37 showed poor
solubility when tested in a high-throughput solubility assay
(HTSA) at a range of pH values, pH 2/6/7.4. The ketone 20
showed improved solubility in the HTSA screens at diﬀerent
pH as well as in the FaSSIF and low pH HCl conditions. The
improved solubility for the ketone versus the amide was likely
to be as a result of the decreased potential for an
intermolecular hydrogen-bonded network. While the methyl-
ene-homologated morpholine 18 was not active, it demon-
strated improved solubility, in particular at low pH as a result
of protonation of the morpholine. The phenyl bioisosteric
replacement 55 also showed improved solubility versus 37,
presumably as it is devoid of the intramolecular interaction
between the thiophene sulfur and carbonyl, Table 9.
Metabolite Identiﬁcation. In order to be able to address
and modify the metabolically labile moieties in the compound
series, the in vivo metabolites of 37 were determined. The
main metabolites observed were the products of oxidation of
the morpholine, whereas de-ethylation was observed only in
small quantities (Supporting Information Table 3).
Eﬃcacy Studies. Compound 37 was proﬁled in an acute 4
day screening model of TB infection to determine if it had in
vivo eﬃcacy (infected with H37Rv).31 The compound was
compared to moxiﬂoxacin as the known control agent. The
compounds were dosed orally at 100 mg/kg, and 37 showed a
small but signiﬁcant 0.8 log reduction of colony forming unit
(CFU) counts in the lungs (Table 10). The in vivo eﬃcacy,
coupled with the understanding of the optimization parame-
ters, led us to further investigate the mode of action for the
series.
Mode of Action Studies. Since the SAR suggested that
the phenethyl linker and the amide carbonyl were critical
aspects of the minimum pharmacophore, it appeared that the
series shared a similar pharmacophore to a number of reported
scaﬀolds targeting QcrB.24 QcrB is a subunit of the
menaquinol cytochrome c oxidoreductase (bc1 complex) that
is part of the bc1-aa3-type cytochrome c oxidase complex and
is responsible for driving oxygen-dependent respiration.21,22,32
A number of inhibitors of QcrB have been identiﬁed recently
through phenotypic screens,21,33−36 and Q203 is currently
undergoing clinical development. Overlay of selected low local
energy conformations of 37 with Q20321 highlights the
similarity in the pharmacophore (Figure 2).
To test this hypothesis, a set of active compounds was tested
against mutant strains of M. tuberculosis each with a single
nucleotide polymorphism in QcrB; we used a QcrBT313I
mutant since this was previously shown to confer resistance
to multiple QcrB inhibitors including Q203 and the
imidazopyridines, as well as QcrBM342T (Table 11).
21,24 A
homology model for the structure of QcrB has been reported
previously based on multiple cytochrome b homologues,24 and
the mutated residues map to the stigmatellin binding site
within the bc1 complex modifying the shape of the binding
pocket.24,37 The mutant strains were resistant to the panel of
compounds chosen, with an increase in MIC of over 10-fold
versus the wild-type (WT) strain. As for other QcrB
inhibitors,21,24,35 the resistant mutant data suggests that the
MOT series targets QcrB directly acting like stigmatellin and
disrupting electron transport.
To explore further the eﬀect of the MOT compounds on
QcrB, it was determined whether exposure resulted in a
decrease in ATP levels, as would be expected for compounds
which target QcrB.21,34 ATP and growth were monitored in
the same experiment, and it was clear that ATP levels were
Table 3. Morpholine Side Chain SAR
aMinimum inhibitory concentration (MIC90) is the minimum
concentration required to inhibit the growth of M. tuberculosis in
liquid culture. Data are the average ± standard deviation of a
minimum of two independent experiments; numbers of experiments
is given (n). bInhibitory concentration (IC50) is the concentration
required to inhibit growth of Vero cells by 50%. Data are the average
± standard deviation of a minimum of two independent experiments;
numbers of experiments is given (n). cIntrinsic clearance (Cli) using
CD1 mouse liver microsomes
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depleted in a dose-dependent manner (Figure 3) as seen
previously for compounds that also target QcrB.21,34,35,38 The
depletion of ATP occurred at lower concentrations than
required to inhibit growth, as for Q203 (a known QcrB
inhibitor), suggesting that this is the mode of action. In
contrast, depletion of ATP by rifampicin which targets RNA
polymerase correlated with growth. These data support the
conclusion that the MOT series targets QcrB.
■ CONCLUSION
We describe the identiﬁcation of a novel morpholino−
thiophene series from whole cell screening against M.
tuberculosis. The conﬁrmed hit 1 was extensively proﬁled,
and the proﬁle suggested that microsomal stability was a key
optimization parameter. Structure−activity relationships led to
an understanding of the minimal pharmacophore as well as
emerging leads such as 37 with improved whole cell activity
Table 4. Phenyl Ring and Ethyl Linker SAR
aMinimum inhibitory concentration (MIC90) is the minimum concentration required to inhibit the growth of M. tuberculosis in liquid culture. Data
are the average ± standard deviation of a minimum of two independent experiments; numbers of experiments is given (n). bInhibitory
concentration (IC50) is the concentration required to inhibit growth of Vero cells by 50%. Data are the average ± standard deviation of a minimum
of two independent experiments; numbers of experiments is given (n). cIntrinsic clearance (Cli) using CD1 mouse liver microsomes
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against M. tuberculosis and improved microsomal stability.
Selected compounds were proﬁled in an acute in vivo eﬃcacy
model of TB, and 37 was found to have a small but signiﬁcant
eﬀect. Mode of action proﬁling suggested the series targets
QcrB, a subunit of the menaquinol cytochrome c oxidor-
eductase (bc1 complex) involved in bacterial respiration. In
contrast to Q203, the novel lead series reported herein
provides starting points with scope for optimization to reduce
the high log P associated with Q203. Further lead optimization
eﬀorts will be reported elsewhere.
■ EXPERIMENTAL SECTION
Determination of Minimum Inhibitory Concentration
(MIC90). MICs were determined against M. tuberculosis H37Rv
(ATCC 25618) and mutant strains grown in Middlebrook 7H9
medium containing 10% v/v OADC (oleic acid, albumin, dextrose,
catalase) supplement (Becton Dickinson) and 0.05% w/v Tween 80
(7H9-Tw-OADC) under aerobic conditions as previously de-
scribed.39 Bacterial growth was measured after 5 days of incubation
at 37 °C. MIC90 was deﬁned as the concentration of compound
required to inhibit growth of M. tuberculosis by 90% and was
determined by plotting growth and curve ﬁtting using the Levenberg−
Marquardt least-squares plot.
Cytotoxicity Assay. The Vero cell line (ATCC CRL-1587) was
grown in DMEM, high glucose, GlutaMAX (Invitrogen), 10% fetal
bovine serum (FBS), and 1× penicillin−streptomycin solution (100
U/mL). Compounds were solubilized in DMSO and assayed as a 10-
point 3-fold serial dilution. Compounds were incubated with cells for
2 days at 37 °C, 5% CO2. CellTiter-Glo Reagent (Promega) was
added and relative luminescent units (RLU) measured. Inhibition
curves were ﬁtted using the Levenberg−Marquardt algorithm; TC50
was calculated as the compound concentration giving 50% inhibition
of growth.
Measurement of Intrabacterial ATP Levels. M. tuberculosis
H37Rv was exposed to compounds for 24 h. ATP levels were
measured using the BacTiter-Glo assay kit (Promega) and expressed
as RLU (relative luminescence units). Growth was monitored by
OD590.
Intrinsic Clearance (Cli) Experiments. Test compound (0.5
μM) was incubated with female CD1 mouse liver microsomes
(Xenotech LLC; 0.5 mg/mL 50 mM potassium phosphate buﬀer, pH
7.4) and the reaction started with addition of excess NADPH (8 mg/
mL 50 mM potassium phosphate buﬀer, pH 7.4). Immediately, at
time zero, and then at 3, 6, 9, 15, and 30 min an aliquot (50 μL) of
Table 5. Core Replacement SAR
aMinimum inhibitory concentration (MIC90) is the minimum
concentration required to inhibit the growth of M. tuberculosis in
liquid culture. Data are the average ± standard deviation of a
minimum of two independent experiments; numbers of experiments
is given (n). bInhibitory concentration (IC50) is the concentration
required to inhibit growth of Vero cells by 50%. Data are the average
± standard deviation of a minimum of two independent experiments;
numbers of experiments is given (n). cIntrinsic clearance (Cli) using
CD1 mouse liver microsomes
Table 6. Oral (10 mg/kg) and IV (3 mg/kg) Pharmacokinetic Proﬁles in Female C57 Mice for 1, 55, 37, 45, and 25 Based on
Mouse Clearance and MIC Potency
ID
H37Rv MIC,a
ng/mL
in vitro mouseb Clint,
mL/min/g route
Cmax
ng/mL
T1/2,
h
AUC
ng-min/mL
scaled Clpre,
c
mL/min/kg
CLB,
mL/min/kg
Vdss,
L/kg % F
1 130 19 IV 0.7 290 000 81 10 0.5 0.5
PO 8 5300
55 1900 4 IV 1.2 95 200 68 32 0.9 5
PO 280 15 000
37 83 8 IV 104 000 76 29 1.7 18
PO 430 64 000
46 >6200 2.1 IV 0.7 980 000 56 31 0.8 38
PO 1700 123 000
25 640 <0.5 PO 160 5200
aMinimum inhibitory concentration (MIC90) is the minimum concentration required to inhibit the growth of M. tuberculosis in liquid culture. Data
are the average ± standard deviation of a minimum of two independent experiments; numbers of experiments is given (n). bIntrinsic clearance
(Cli) using CD1 mouse liver microsomes. cScaled predicted Clb (Clpre) using well stirred model.
Table 7. HPV Study on 37
IV
1 mg/kg
PO HPV
5 mg/kg
PO Cardiac
5 mg/kg
Cmax (ng/mL) 200 140
Tmax (h) 1 1
T1/2 (h) 0.5
AUC 0−24 (ng-min−1mL) 33 000 35 000 19 000
Clb 30
Vdss (L/kg) 1.1
F (%) 12
hepatic extraction ratio
(ER)
0.4
fraction of dose absorbed
(Fa)
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the incubation mixture was removed and mixed with acetonitrile (100
μL) to stop the reaction. Internal standard was added to all samples,
the samples centrifuged to sediment precipitated protein, and the
plates then sealed prior to UPLCMSMS analysis using a Quattro
Premier XE (Waters Corp., USA). XLﬁt (IDBS, UK) was used to
calculate the exponential decay and consequently the rate constant
(k) from the ratio of peak area of test compound to internal standard
at each time point. The rate of intrinsic clearance (CLi) of each test
compound was then calculated using the following calculation
= × ×k VCLi(mL/min /g liver) microsomal protein yield
where V (mL/mg protein) is the incubation volume/mg protein
added and microsomal protein yield is taken as 52.5 mg protein/g
liver. Verapamil (0.5 μM) was used as a positive control to conﬁrm
acceptable assay performance. The human biological samples were
sourced ethically, and their research use was in accord with the terms
of the informed consents.
Aqueous Solubility. The aqueous solubility of the test
compounds was measured using laser nephelometry. Compounds
were subject to serial dilution from 10 to 0.5 mM in DMSO. An
aliquot was then mixed with Milli-Q water to obtain an aqueous
dilution plate with a ﬁnal concentration range of 250−12 μM, with a
ﬁnal DMSO concentration of 2.5%. Triplicate aliquots were
transferred to a ﬂat-bottomed polystyrene plate which was
immediately read on the NEPHELOstar (BMG Lab Technologies).
The amount of laser scatter caused by insoluble particulates (relative
nephelometry units, RNU) was plotted against compound concen-
tration using a segmental regression ﬁt, with the point of inﬂection
being quoted as the compounds aqueous solubility (μM).
Thermodynamic Solubility via High-Throughput Method,
HTSA. Samples prepared in DMSO were dried for 12 h. The powder
or ﬁlm was redissolved in the solvent at various pH (2, 6, and 7.4) and
DMSO control at 2 mM target concentration. Samples are stirred for
20 h and ﬁltered through a 0.7 μm GF ﬁlter. The ﬁltrate was analyzed
by HPLC assay for concentration against DMSO standard curve.40
Mouse Pharmacokinetics. Test compound was dosed as a bolus
solution intravenously at 3 mg of free base/kilogram (dose volume 5
mL/kg; dose vehicle Saline or 10% DMSO; 40% PEG400; 50%
saline) to female C57 Black (n = 3) or dosed orally by gavage as a
solution at 10 mg of free base/kilogram (dose volume 10 mL/kg;
dose vehicle 10% DMSO; 40% PEG400; 50% distilled water) to
female C57 Black (n = 3/dose level). Blood samples were taken from
each mouse tail vein at predetermined time points postdose, mixed
with two volumes of distilled water, and stored frozen until UPLC/
MS/MS analysis. Pharmacokinetic parameters were derived from the
blood concentration time curve using PK Solutions software v 2.0
(Summit Research Services, USA).
Therapeutic Eﬃcacy of 37 against M. tuberculosis in an
Acute Murine Model of Intratracheal Infection. Speciﬁc
pathogen-free, 8−10 week old female C57BL/6 mice were purchased
from Harlan Laboratories and allowed to acclimate for 1 week. Mice
were intrathecal infected with 100.000 CFU/mouse (M. tuberculosis
H37Rv strain). Compound 39 was administered for 4 consecutive
days starting 5 days after the infection. Moxiﬂoxacin was used as an
interassay control and administered for 8 consecutive days starting 1
day after the infection. Lungs were harvested on day 9, 24 h after the
last administration. All lung lobes were aseptically removed,
homogenized, and frozen. Homogenates were plated in 10%
Table 8. MDCK Proﬁling of Selected Compounds
ID MW log P TPSA HBD A → B Papp 1 × 10e−6 cm/s B → A Papp 1 × 10e−6 cm/s P-gp Eﬄux B→ A/A → B
Quinidine 324 2.6 45 1 4 89 20
Verapamil 454 3.8 64 0 14 29 2
Atenolol 266 0.2 85 4 1 1 1
Metoprolol 267 1.8 51 2 55 40 0.7
1 332 2.6 65 2 45 37 0.8
37 416 3.3 74 2 25 20 0.8
18 346 2.2 65 2 62 53 0.8
46 312 1.1 74 2 19 35 2
56 344 2.8 65 2 51 37 0.7
Table 9. Measured Solubility Data for Selected Compounds
pH 2.4, pH 6 pH 2 pH 6 pH 7.4
0.01 N HCl FaSSIF HTSA HTSA HTSA
ID mg/mL mg/mL mg/mL mg/mL mg/mL
20 0.4 0.2 0.6 0.03 0.03
18 1.7 0.04 0.7 0.1 0.3
55 1.3 0.3 0.6 0.3 0.3
37 ND ND 0.002 0.001 0.001
Table 10. Eﬃcacy of 37 against M. tuberculosis in an Acute
Murine Model of Intratracheal Infection
log CFUs per mouse (lungs)
1 2 3 4 5 mean SD
no treatment (day 9) 6.8 6.8 6.5 6.9 7.0 6.8 0.2
Moxiﬂoxacin: 30 mg/kg
8 days
3.8 4.4 4.0 3.9 3.8 4.0 0.3
37: 100 mg/kg 4 days 6.1 5.8 6.0 0.2
Figure 2. Overlay of known QcrB inhibitor Q203 (green) with 37
(yellow). Further 2D comparison of QcrB pharmacophores is shown
in the Supporting Information (Table 1).
Table 11. Screening of Selected Compounds against M.
tuberculosis QcrB Mutant Strains
MICa (μM)
ID WTb T313Ic fold shift M342Td fold shift
1 1.3 53 41 25 19
21 0.08 >20 >250 4.8 60
35 5.8 >50 >8.6 >20 >3
37 0.24 11 46 ND ND
39 0.53 59 110 7 14
aMinimum inhibitory concentration (MIC90) is the minimum
concentration required to inhibit the growth of M. tuberculosis in
liquid culture. bWild-type strain. cQcrB T313I mutant strain. dQcrB
M342T mutant strain. ND Not Done
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OADC-7H11 medium supplemented with activated charcoal 0.4% for
18 days at 37 °C. All animal studies were ethically reviewed and
carried out in accordance with European Directive 2010/63/EEC and
the GSK Policy on the Care, Welfare and Treatment of Animals. The
number of CFU/mouse measured for each mouse is shown in Table
10. The diﬀerences in the lung microorganism burden (log 10 CFUs/
lungs) obtained in the treated mice with respect to untreated controls
(day 9 after infection) are shown in Table 10. No adverse clinical
signs were observed in any animal. Moxiﬂoxacin (30 mg/kg) reduced
2.8 logs the CFU lung number with respect to untreated mice. This
quality control value is included in the accepted interval. CFU
number in lungs of untreated mice: 6.8 log CFU. This value is inside
the interval mean ±2 SD of the values of the last experiments. In these
experimental conditions, 37 was able to inhibit the growth of the
bacteria in the lungs of the mice compared to untreated mice. This
diﬀerence was statistically signiﬁcant.
Rat Hepatic Portal Vein (HPV) Study. Test compound was
dosed orally by gavage at 5 mg of free base/kilogram (dose volume 5
mL/kg; dose vehicle 1.0% carboxy methyl cellulose, CMC) to male
Sprague−Dawley Rats (n = 1 per time point). At predetermined time
points, blood samples (100 μL) were taken from the hepatic portal
vein into a tube containing EDTA. Immediately afterward, the
remaining blood was taken by cardiac puncture into a separate tube
containing EDTA to determine the concentration of compound
reaching the systemic circulation. The blood was mixed with two
volumes of distilled water and stored frozen until UPLC/MS/MS
analysis. Pharmacokinetic parameters were derived from the blood
concentration time curve using PK Solutions software v 2.0 (Summit
Research Services, USA).
General Chemistry Methods. Chemicals and solvents were
purchased from commercial vendors and were used as received, unless
otherwise stated. Dry solvents were purchased in Sure Seal bottles
stored over molecular sieves. Unless otherwise stated herein reactions
have not been optimized. Analytical thin-layer chromatography
(TLC) was performed on precoated TLC plates (Kieselgel 60
F254, BDH). Developed plates were air dried and analyzed under a
UV lamp (UV 254/365 nm) and/or KMnO4 was used for
visualization. Flash chromatography was performed using Combiﬂash
Companion Rf (Teledyne ISCO) and prepacked silica gel columns
purchased from Grace Davison Discovery Science or SiliCycle. Mass-
directed preparative HPLC separations were performed using a
Waters HPLC (2545 binary gradient pumps, 515 HPLC makeup
pump, 2767 sample manager) connected to a Waters 2998
photodiode array and a Waters 3100 mass detector. Preparative
HPLC separations were performed with a Gilson HPLC (321 pumps,
819 injection module, 215 liquid handler/injector) connected to a
Gilson 155 UV/vis detector. On both instruments, HPLC chromato-
graphic separations were conducted using Waters XBridge C18
columns, 19 mm × 100 mm, 5 μm particle size, using 0.1% ammonia
in water (solvent A) and acetonitrile (solvent B) as mobile phase.1H
NMR spectra were recorded on a Bruker Advance II 500, 400, or 300
spectrometer operating at 500, 400, or 300 MHz (unless otherwise
stated) using CDCl3 or DMSO-d6 solutions. Chemical shifts (δ) are
expressed in ppm recorded using the residual solvent as the internal
reference in all cases. Signal splitting patterns are described as singlet
Figure 3. ATP levels were measured in M. tuberculosis exposed to compounds for 24 h. Growth was monitored by OD590: (A−D) MOT
compounds, (E) Q203, and (F) Rifampicin. Results are representative of 2 independent experiments.
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(s), doublet (d), triplet (t), multiplet (m), broadened (b), or a
combination thereof. Coupling constants (J) are quoted to the nearest
0.1 Hz (Hz). Low-resolution electrospray (ES) mass spectra were
recorded on a Bruker Daltonics MicrOTOF mass spectrometer run in
positive mode. High-resolution mass spectroscopy (HRMS) was
performed using a Bruker Daltonics MicrOTOF mass spectrometer.
LC-MS analysis and chromatographic separation were conducted with
a Bruker Daltonics MicrOTOF mass spectrometer or an Agilent
Technologies 1200 series HPLC connected to an Agilent
Technologies 6130 quadrupole LC/MS where both instruments
were connected to an Agilent diode array detector. The column used
was a Waters XBridge column (50 mm × 2.1 mm, 3.5 μm particle
size), and the compounds were eluted with a gradient of 5−95%
acetonitrile/water + 0.1% ammonia. All ﬁnal compounds showed
chemical purity of ≥95% as determined by the UV chromatogram
(190−450 nm) obtained by LC-MS analysis. High-resolution
electrospray measurements were performed on a Bruker MicroTof
mass spectrometer. Microwave-assisted chemistry was performed
using a CEM microwave synthesizer.
5-Morpholino-3-phenethoxythiophene-2-carboxamide (1). 7
(200 mg, 0.88 mmol), 2-iodoethylbenzene (224 mg, 0.96 mmol),
and K2CO3 (121 mg, 0.88 mmol) were dissolved in MeCN and
heated for 15 min at 120 °C in μW. Excess MeCN was removed in
vacuo and the crude residue partitioned between EtOAc/H2O, the
organic solvent was removed in vacuo, and the residue was puriﬁed by
column chromatography eluting with 0−100% EtOAc in heptanes to
aﬀord the desired product, colorless solid (60 mg, 21%). 1H NMR
(500 MHz, CDCl3) δ 7.36 (dd, J = 7.3, 7.3 Hz, 2H), 7.27−7.26 (m,
1H), 5.83 (s, 1H), 4.36 (dd, J = 6.7, 6.7 Hz, 2H),3.85−3.82 (m, 4H),
3.21−3.12 (m, 6H). HRMS (ES + ve), C17H20N2O3S [M + H]+: calcd
333.1267, found 333.1261.
Methyl 3-[2-ethoxyethyl(methyl)amino]-3-oxo-propanoate (5).
Morpholine (5.0 g, 57 mmol) and dimethylpropanedioate (11.4 g, 86
mmol) were heated at 60 °C for 16 h. The reaction was stopped, and
the excess reagent was removed in vacuo. The crude mixture was
taken on to the next step without further puriﬁcation (9.7 g, 90%). 1H
NMR (300 MHz, CDCl3) δ 3.69−3.68 (s, 3H), 3.65−3.56 (m, 6H),
3.41 (s, 2H), 3.38 (d, J = 4.5 Hz, 2H). LC-MS m/z 204 [M + H]+.
Methyl 3-morpholino-3-thioxopropanoate (6). 5 (28.1 g, 150
mmol) was dissolved in 1,4-dioxane (72 mL), and Lawesson’s
Reagent (34.0 g, 84 mmol) was added. The reaction was heated to
100 °C for 2 h, stopped, and cooled to 0 °C. The resulting precipitate
was ﬁltered washing with EtOAc, the ﬁltrate was washed with
NaHCO3 (100 mL), and the organic layer was dried though a
hydrophobic frit before being concentrated in vacuo to aﬀord an
orange oil. Trituration with Et2O aﬀorded the desired product as a
pale orange solid (22.5 g, 74%). 1H NMR (500 MHz, CDCl3) δ 4.38
(t, J = 5.0 Hz, 2H), 4.09 (s, 2H), 3.84 (t, J = 5.0 Hz, 2H), 3.82−3.79
(m, 2H), 3.79 (s, 3H), 3.77−3.75 (m, 2H). LC-MS m/z 204 [M +
H].
3-Hydroxy-5-morpholino-thiophene-2-carboxamide (7). Sodium
hydride (1.2 g, 29.5 mmol) was dissolved in THF (18 mL) at rt, and 6
(6.0 g, 29.5 mmol) was added. The reaction was stirred at rt for 30
min and then cooled to 0 °C. 2-Bromoacetamide (4.1 g, 29.5 mmol)
was added. The reaction was maintained at 0 °C for a further 1 h,
then warmed to rt, and stirred for a further 2 h. A second equivalent of
NaH (1.2 g, 29.5 mmol) was added, and the reaction was stirred at rt
for 2 h. LCMS indicated that the desired product had formed. The
reaction was quenched with water, and excess THF was removed in
vacuo. The aqueous layer was acidiﬁed with 1 M HCl and partitioned
with EtOAc. The desired product precipitated from the organic
extracts (6.7 g, 65%). 1H NMR (500 MHz, CDCl3) δ 11.91 (bs, 1H),
7.00 (bs, 2H), 5.83 (s, 1H), 4.37 (J = 5.1 Hz, 4H), 5.11 (J = 5.1 Hz,
4H). LC-MS m/z 479 [2 M + Na].
General Procedure A: LDA. Thiophene derivative (1 equiv) was
added to a ﬂame-dried ﬂask under N2 and dry THF (4 mL/mmol)
added. The solution was cooled to −78 °C, and LDA (1.1 equiv) was
added dropwise. The reaction mixture was stirred for 5 min, and
iodine (1.1 equiv) was added. The reaction was further stirred for 10
min at −78 °C, then warmed to rt for 3 h, quenched with water, and 1
N HCl (1 mL/mmol) added. The organic phase was separated and
washed with an aqueous solution of sodium bisulphite and dried over
MgSO4, and the solvent was removed in vacuo. The crude material
was triturated with hexane to aﬀord the desired product.
Methyl 5-Iodo-3-(2-phenylethoxy)thiophene-2-carboxylate (12).
Prepared using general procedure A starting from methyl 3-(2-
phenylethoxy)thiophene-2-carboxylate (2.5 g, 9.5 mmol), pale yellow
solid (2.2 g, 60%). 1H NMR (300 MHz, CDCl3) δ 7.35−7.28 (m,
5H), 6.98 (s, 1H), 4.30 (2H, t, J = 7.1 Hz), 3.85 (3H, s), 3.16 (2H, t, J
= 7.0 Hz). LC-MS m/z 389 [M + H].
5-Iodo-3-(2-phenylethoxy)thiophene-2-carboxamide (13). Pre-
pared using general procedure B starting from 12 (600 mg, 1.55
mmol), pale yellow solid (432 mg, 75%). 1H NMR (300 MHz,
CDCl3) δ 7.38−7.26 (m, 5H), 7.04 (s, 1H), 6.62 (br.s, 1H), 5.27
(br.s, 1H), 4.39 (t, J = 6.6 Hz, 2H), 3.14 (t, J = 6.6 Hz, 2H). LC-MS
m/z 374 [M + H].
Methyl 5-Morpholino-3-(2-phenylethoxy)thiophene-2-carboxy-
late (14). 12 (1500 mg, 3.9 mmol), Cs2CO3 (1888 mg, 5.8 mmol),
RuPhos (361 mg, 0.77 mmol), and Pd2(dba)3 (177 mg, 0.19 mmol)
were placed in a vial. The vial was sealed, purged, and backﬁlled with
N2 three times. Then dry THF (10 mL) was added followed by
morpholine (438 mg, 5.0 mmol). The sealed vial was heated at 100
°C for 20 h. The reaction was ﬁltered through a Celite pad, and the
solvent was removed in vacuo. The residue was puriﬁed by ﬂash
chromatography eluting with 0−100% EtOAc in hexanes, yellow solid
(943 mg, 70%).1H NMR (CDCl3; 300 MHz) δ 7.37−7.23 (5H, m),
5.78 (1H, s), 4.28 (2H, t, J = 7.2 Hz), 3.85−3.79 (4H, m), 3.81 (3H,
s), 3.22−3.13 (6H, m). HRMS (ES + ve), C18H21NO4S [M + H]+:
calcd 348.1264, found 348.1257.
5-Morpholino-3-(2-phenylethoxy)-N-tetrahydropyran-2-yloxy-
thiophene-2-carboxamide (15). To a solution of 14 (140 mg, 0.40
mmol) and O-tetrahydropyran-2-ylhydroxylamine (47 mg, 0.40
mmol) at −78 °C in dry THF (1.5 mL) was added LiHMDS (1 M
in THF) (1.25 mL, 1.25 mmol) dropwise. The reaction was stirred for
5 min and then allowed to reach rt and stirred overnight. The reaction
mixture was adsorbed onto silica and puriﬁed by column
chromatography eluting with 0−100% EtOAc in heptanes. The
selected fractions were combined, and the solvent was removed in
vacuo to aﬀord the desired product (82 mg, 46%) as a pale brown
solid. 1H NMR (500 MHz, CDCl3) δ 9.29 (s, 1H), 7.39−7.35 (m,
2H), 7.31−7.29 (m, 3H), 5.77 (s, 1H), 5.01 (t, J = 3.1 Hz, 1H), 4.32
(t, J = 6.9 Hz, 2H), 4.05−3.99 (m, 1H), 3.84−3.81 (m, 4H), 3.66−
3.61 (m, 1H), 3.20−3.13 (m, 6H), 1.93−1.82 (m, 3H), 1.71−1.59
(m, 3H). LC-MS m/z 438.1 [M + H], 349 [M + H − THP].
5-Morpholino-3-(2-phenylethoxy)thiophene-2-carbohydroxamic
Acid (16). To a solution of 15 (26 mg, 0.06 mmol) in MeOH (1 mL)
was added p-toluenesulfonic acid monohydrate (1 mg, 0.006 mmol).
The reaction was stirred until no SM was observed by TLC. The
reaction mixture was adsorbed onto silica and puriﬁed by ﬂash
chromatography eluting with 30−100% EtOAc in heptanes, pale
brown solid (12.6 mg, 55%). 1H NMR (400 MHz, CDCl3) δ 8.86 (s,
1H), 7.40−7.38 (m, 2H), 7.32−7.26 (m, 3H), 5.79 (s, 1H), 4.33 (t, J
= 6.5 Hz, 2H), 3.83−3.81 (m, 4H), 3.19−3.13 (m, 6H). LC-MS m/z
350 [M + H].
Methyl 5-Formyl-3-(2-phenylethoxy)thiophene-2-carboxylate
(18a). Prepared using general procedure A starting from methyl 3-
(2-phenylethoxy)thiophene-2-carboxylate (400 mg, 1.5 mmol), color-
less oil (440 mg, 99%). 1H NMR (300 MHz, CDCl3) δ 9.74 (s, 1H),
7.94 (s, 1H), 7.27−7.24 (m, 2H), 7.22−7.17 (m, 3H), 4.28 (t, J = 7.0
Hz, 2H), 3.82 (s, 3H), 3.09 (t, J = 7.0 Hz, 2H). LC-MS m/z 313 [M
+ Na].
Methyl 5-(Morpholinomethyl)-3-(2-phenylethoxy)thiophene-2-
carboxylate (18b). A mixture of morpholine (159 mg, 1.83 mmol)
and 18a (443 mg, 1.53 mmol) was dissolved in chloroform (10 mL)
and stirred at rt for 1 h. Then NaBH(OAc)3 (485 mg, 2.29 mmol)
was added, and the mixture was stirred in a sealed tube for 20 h. The
mixture was diluted with water (4 mL), shaken vigorously, and ﬁltered
through a phase separator, and the ﬁltrate was concentrated in vacuo
to aﬀord a colorless oil (540 mg, 98%). 1H NMR (500 MHz, CDCl3)
δ 7.24−7.23 (m, 4H), 7.19 (s, 1H), 7.17−7.16 (m, 1H), 6.60 (s, 1H),
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4.21 (t, J = 7.2 Hz, 2H), 3.76 (s, 3H), 3.68−3.63 (m, 4H), 3.52 (s,
2H), 3.07 (t, J = 7.2 Hz, 2H), 2.44−2.40 (m, 4H). LC-MS m/z 362
[M + H].
General Procedure B: Using CaCl2 To Form the Primary
Amide. Acid (1 equiv) and CaCl2 (1.2 equiv) were added to a
solution of NH3 in MeOH (7 M) (20 equiv). The vessel was sealed,
and the mixture was stirred at 150 °C for 3 h under microwave
conditions. The reaction mixture was diluted with DCM and a
saturated aqueous solution of NH4Cl, and the organic phase was
separated through a hydrophobic frit and concentrated in vacuo. The
crude material was puriﬁed by ﬂash chromatography eluting with 20−
100% EtOAc in heptanes.
5-(Morpholinomethyl)-3-(2-phenylethoxy)thiophene-2-carboxa-
mide (18). Prepared by general procedure B starting from 18b (551
mg, 1.53 mmol), pale yellow solid (172 mg, 31%). 1H NMR (300
MHz, CDCl3) δ 7.41−7.30 (m, 4H), 7.27−7.24 (s, 1H), 6.77−6.73
(m, 2H), 5.32 (br.s, 1H), 4.40 (t, J = 6.7 Hz, 2H), 3.76−3.71 (m,
4H), 3.62 (s, 2H), 3.15 (t, J = 6.7 Hz, 2H), 2.55−2.49 (m, 4H).
HRMS (ES + ve), C18H23N2O3S [M + H]
+: calcd 347.1424, found
347.1442.
4-[4-(2-Phenylethoxy)-2-thienyl]morpholine (19). tButyl 5-mor-
pholino-3-(2-phenylethoxy)thiophene-2-carboxylate (73 mg, 0.19
mmol) was dissolved in MeOH (7 mL), and KOH (316 mg, 5.62
mmol) was added. The reaction mixture was heated to reﬂux for 26 h
and cooled, and the solvent was removed in vacuo. H2O was added to
the residue that was acidiﬁed with 2 M HCl and extracted with DCM
(2 × 10 mL). The combined organics were dried and puriﬁed by
column chromatography eluting with 20% EtOAc in heptane,
colorless oil (5 mg, 8%). 1H NMR (CDCl3; 500 MHz) δ 7.28−
7.13 (5H, m), 5.76 (1H, s), 5.44 (1H, s), 4.03 (2H, t, J = 7.1 Hz),
3.77−3.70 (4H, m), 3.03−2.95 (6H, m). LC-MS m/z 289 [M + H].
3-Hydroxy-5-morpholinothiophene-2-carbonitrile (20a). NaOEt
(10.4 g, 32 mmol) was dissolved in EtOH (90 mL), and 6 (5.00 g,
24.6 mmol) was added. The mixture was then cooled to 0 °C, and 2-
bromoacetonitrile (2.95 mg, 24.6 mmol) was added. The reaction was
stirred at 0 °C for 1 h and then allowed to warm to rt for a further 1 h
before addition of further NaOEt (2.18 g, 31.98 mmol). The reaction
was stirred for 12 h at rt. The precipitate was ﬁltered and dissolved in
H2O before acidifying with 1 M HCl and extracting with DCM (3 ×
50 mL). The combined organics were dried through a hydrophobic
frit and concentrated in vacuo. The resulting solid was triturated with
Et2O and ﬁltered oﬀ to aﬀord a beige solid (2.83 g, 55%).
1H NMR
(CDCl3; 500 MHz) δ 5.25 (1H, s), 4.56 (1H, s), 3.82 (4H, t, J = 4.9
Hz), 3.49 (4H, t, J = 4.9 Hz). LC-MS m/z 211 [M + H].
5-Morpholino-3-(2-phenylethoxy)thiophene-2-carbonitrile
(20b). 20a (1.50 g, 7.1 mmol), Cs2CO3 (3.49 g, 10.7 mmol), and 2-
bromoethylbenzene (1.98 g, 10.7 mmol) were combined in MeCN
(15 mL) and heated in the microwave at 120 °C for 30 min. The
reaction mixture was extracted with DCM (2 × 10 mL), washing with
H2O (15 mL). The organics were dried through a hydrophobic frit
and concentrated in vacuo to aﬀord an orange oil. The crude material
was columned eluting with 20−100% EtOAc in hexane to aﬀord an
oﬀ-white solid (844 mg, 37%). 1H NMR (CDCl3; 500 MHz) δ 7.37−
7.32 (2H, m), 7.31−7.25 (4H, m), 5.66 (1H, s), 4.39 (2H, t, J = 7.0
Hz), 3.85−3.81 (4H, m), 3.19−3.16 (4H, m), 3.11 (2H, t, J = 7.0
Hz). LC-MS m/z 315 [M + H].
1-[5-Morpholino-3-(2-phenylethoxy)-2-thienyl]ethanone (20).
MeMgBr (53 mg, 0.45 mmol) was dissolved in toluene (5 mL)
under N2, and 20b (70 mg, 0.22 mmol) was added. The mixture was
heated to reﬂux for 3 h. The reaction mixture was allowed to cool to rt
before acidifying with 2 M HCl to pH 2. The mixture was then heated
to reﬂux for 30 min. The mixture was allowed to cool to rt and
basiﬁed with a saturated aqueous NaHCO3 solution and extracted
with EtOAc (2 × 15 mL). The organics were dried through a phase
separating frit and concentrated in vacuo to aﬀord an orange oil which
solidiﬁed on standing at rt. The crude material was columned eluting
with 0−20% MeOH in DCM, pink solid (2 mg, 2%). 1H NMR
(CDCl3; 500 MHz) δ 7.30−7.23 (2H, m), 7.21−7.17 (3H, m), 5.67
(1H, s), 4.22 (2H, t, J = 6.8 Hz), 3.75−3.71 (4H, m), 3.18−3.14 (4H,
m), 3.05 (2H, t, J = 6.8 Hz), 2.29 (3H, s). HRMS (ES + ve),
C18H21NO3S [M + H]
+: calcd 332.1315, found 332.1314.
3-Hydroxy-N-methyl-5-morpholinothiophene-2-carboxamide
(21a). NaOEt (1.04 g, 3.20 mmol) was dissolved in EtOH (9 mL),
and methyl 6 (500 mg, 2.5 mmol) was added. The mixture was then
cooled to 0 °C, and 2-bromo-N-methyl-acetamide (374 mg, 2.46
mmol) was added. The reaction was stirred at 0 °C for 1 h and then
allowed to warm to rt for a further 1 h before addition of further
NaOEt (218 mg, 3.2 mmol). The reaction was then stirred at rt for 2
h. The reaction was quenched with H2O, and the volatiles were
removed in vacuo. The mixture was acidiﬁed using 2 M HCl and
extracted with DCM (2 × 20 mL). The combined organics were dried
and concentrated in vacuo to aﬀord an oﬀ-white solid which was
puriﬁed by column chromatography eluting with 5% MeOH in DCM
to aﬀord the desired product as a white solid (127 mg, 21%). 1H
NMR (CDCl3; 300 MHz) δ 7.90 (1H, br s), 5.21 (1H, s), 4.69 (1H,
s), 3.83−3.75 (4H, m), 3.54−3.45 (4H, m), 2.86 (3H, t, J = 4.8). LC-
MS m/z 243 [M + H].
N-Methyl-5-morpholino-3-(2-phenylethoxy)thiophene-2-carbox-
amide (21). 21a (127 mg, 0.52 mmol), Cs2CO3 (256 mg, 0.79
mmol), and 2-bromoethylbenzene (146 mg, 0.79 mmol) were
combined in MeCN (2 mL) and heated in the microwave at 120
°C for 30 min. The reaction mixture was extracted with DCM (2 × 10
mL), washing with H2O (15 mL). The organics were dried through a
phase-separating frit and concentrated in vacuo to aﬀord a brown oil.
The crude material was columned eluting with 3% MeOH in DCM. It
was puriﬁed further using the Waters autoprep acidic (20−95%),
colorless solid (45 mg, 25%). 1H NMR (CDCl3; 500 MHz) δ 7.39−
7.33 (2H, m), 7.31−7.25 (3H, m), 6.52 (1H, br s), 5.83 (1H, s), 4.35
(2H, t, J = 6.4 Hz), 3.83−3.79 (4H, m), 3.17−3.13 (4H, m), 3.10
(2H, t, J = 6.4 Hz), 2.76 (3H, d, J = 4.9 Hz). HRMS (ES + ve),
C18H22N2O3S [M + H]
+: calcd 347.1424, found 347.1443.
General Procedure C: AlCl3-Catalyzed Amide Formation.
Acid (1 equiv) and trimethylaluminum in toluene (4 equiv) were
stirred at rt, and ethanamine (1 equiv) was added. The reaction was
heated at reﬂux for 3 h, stopped, and cooled to rt. Excess solvent was
removed in vacuo; 1 M NaOH was added (20 mL/mmol), and the
mixturewas extracted with EtOAc. The organic layer was dried in
vacuo, and the crude residue was puriﬁed by column chromatography
eluting with DCM to 10% DCM.
N-Ethyl-5-morpholino-3-(2-phenylethoxy)thiophene-2-carboxa-
mide (22). Prepared using general procedure C starting from 14 (50
mg, 0.14 mmol), colorless solid (77 mg, 88%). 1H NMR (400 MHz,
CDCl3) δ 7.38−7.35 (m, 2H), 7.30−7.27 (m, 3H), 6.63 (bs, 1H),
5.84 (s, 1H), 4.36 (dd, J = 6.5, 6.5 Hz, 2H), 3.83 (dd, J = 4.7, 4.7 Hz,
4H), 3.34−3.25 (m, 2H), 3.19−3.10 (m, 6H), 1.07 (dd, J = 7.2, 7.2
Hz, 3H). HRMS (ES + ve), C19H25N2O3S [M + H]
+: calcd 361.1589,
found 361.1580.
5-Morpholino-3-phenethoxy-N-(2,2,2-triﬂuoroethyl)thiophene-
2-carboxamide (23). Prepared using general procedure C starting
from 14 (50 mg, 0.14 mmol), colorless solid (20 mg, 33%). 1H NMR
(500 MHz, CDCl3) δ 7.37 (dd, J = 7.3, 7.3 Hz, 2H), 7.31−7.27 (m,
3H), 6.93 (dd, J = 6.3, 6.3 Hz, 1H), 5.82 (s, 1H), 4.39 (dd, J = 6.6, 6.6
Hz, 2H), 3.92−3.82 (m, 6H), 3.21−3.12 (m, 6H). HRMS (ES + ve),
C19H22F2N2O3S [M + H]
+: calcd 415.1313, found 415.1298.
N-Cyclobutyl-5-morpholino-3-phenethoxythiophene-2-carboxa-
mide (24). Prepared using general procedure C starting from 14 (50
mg, 0.14 mmol), colorless solid (17 mg, 30%). 1H NMR (400 MHz,
CDCl3) δ 7.40−7.37 (m, 2H), 7.32−7.28 (m, 3H), 6.82 (bs, 1H),
5.84 (s, 1H), 4.52−4.43 (m, 1H), 4.39 (dd, J = 6.5, 6.5 Hz, 2H),
3.85−3.82 (m, 4H), 3.20−3.14 (m, 6H), 2.34−2.28 (m, 2H). HRMS
(ES + ve), C21H27N2O3S (M+H)
+: calcd 387.1737, found 387.1741.
Methyl 5-Morpholino-3-(2-phenylethoxy)thiophene-2-carboxy-
late (25a). 14 (1.5 g, 3.7 mmol), Cs2CO3 (1.9 g, 5.8 mmol), RuPhos
(361 mg, 0.77 mmol), and Pd2(dba)3 (177 mg, 0.19 mmol) were
placed in a vial. The vial was sealed, purged, and backﬁlled with
nitrogen three times. Dry THF (10 mL) was added followed by
morpholine (438 mg, 5.02 mmol). The reaction was heated in a
sealed tube at 100 °C for 20 h. The reaction was ﬁltered through a
Celite pad, and the solvent was removed in vacuo. The crude residue
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was puriﬁed eluting with 0−10% EtOAc in heptane to aﬀord the
desired product as a yellow solid (1231 mg, 92% yield). 1H NMR
(400 MHz, CDCl3) δ 7.34 (d, J = 4.5 Hz, 4H), 7.28−7.26 (m, 1H),
5.77 (s, 1H), 4.27 (dd, J = 7.2, 7.2 Hz, 2H), 3.84−3.81 (m, 6H),
3.22−3.14 (m, 6H), 1.28 (dd, J = 7.2, 7.2 Hz, 1H). LC-MS m/z 348
[M + H].
N-Methoxy-N-methyl-5-morpholino-3-phenethoxythiophene-2-
carboxamide (25). 25a (500 mg, 1.4 mmol) and N,O-dimethylhy-
droxylamine hydochloride (211 mg, 2.15 mmol) were cooled to
approximately −10 °C in THF (3 mL) under nitrogen.
Isopropylmagnesium chloride (488 mg, 4.75 mmol) was then added
dropwise. The reaction was warmed to rt and stirred for 3 h.The
reaction was quenched with water, diluted in DCM, ﬁltered through a
hydrophobic frit, and concentrated in vacuo to aﬀord a yellow oil.
Recrystallization in EtOAc aﬀorded an oﬀ-white solid (420 mg, 74%).
1H NMR (400 MHz, CDCl3) δ 7.34−7.31 (m, 4H), 7.28−7.23 (m,
1H), 5.81 (s, 1H), 4.26 (t, J = 7.6 Hz, 2H), 3.83 (t, J = 4.9 Hz, 4H),
3.72 (s, 3H), 3.27 (s, 3H), 3.21−3.16 (m, 6H). HRMS (ES + ve),
C19H24N2O4S [M + H]
+: calcd 377.1530, found 377.1526.
General Procedure D: Mitsunobu Reaction. Ethyl N-(3-
hydroxy-5-morpholino-thiophene-2-carbonyl)carbamate (1.1 equiv),
alcohol (1 equiv), and polymer-supported triphenylphosphine (1.1
equiv) were dissolved in DCM (15 mL/mmol). DIAD (1.1 equiv)
was dissolved in DCM (12 mL/mmol) and added dropwise to the
mixture. The reaction was stirred for 30 min, ﬁltered, concentrated,
and puriﬁed using prep LCMS to aﬀord the desired product.
Ethyl N-[5-Morpholino-3-(2-phenylethoxy)thiophene-2-
carbonyl]carbamate (26). Prepared using general procedure D
starting from ethyl N-(3-hydroxy-5-morpholino-thiophene-2-
carbonyl)carbamate (100 mg, 0.33 mmol) and 2-phenylethanol (37
mg, 0.30 mmol), colorless solid (134 mg, 10%). 1H NMR (500 MHz,
CDCl3) δ 8.93 (s, 1H), 7.34−7.28 (m, 5H), 5.73 (s, 1H), 4.36 (dd, J
= 6.6, 6.6 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 3.82−3.79 (m, 4H),
3.22−3.13 (m, 6H), 1.34 (dd, J = 7.1, 7.1 Hz, 3H). LC-MS m/z 405
[M + H].
3-(2-Phenylethoxy)thiophene-2-carboxamide (27). Methyl 3-(2-
phenylethoxy)thiophene-2-carboxylate (90 mg, 0.34 mmol) was
dissolved in 7 N NH3 in MeOH (1 mL) and heated to 80 °C for
16 h. The reaction was then heated to 100 °C for 4 h. The reaction
mixture was transferred to a thick-walled vial, and ammonium
hydroxide (33% aqueous, 0.5 mL) was added. The reaction was
heated at 100 °C for 16 h. The volatiles were removed in vacuo to
give a white solid. The residue was puriﬁed by ﬂash chromatography
eluting with 0−40% EtOAc in hexane, and the pure fractions were
concentrated in vacuo to aﬀord the desired product, colorless solid
(27 mg, 30%). 1H NMR (DMSO, 500 MHz) δ 7.69 (d, 1H, J = 5.5
Hz), 7.42 (s, 1H), 7.33−7.32 (m, 4H), 7.26−7.22 (m, 1H), 7.14 (d,
1H, J = 5.5 Hz), 6.69 (s, 1H), 4.42 (t, 2H, J = 6.7 Hz), 3.10 (t, 2H, J =
6.6 Hz). HRMS (ES + ve), C13H14NO2S [M + H]
+: calcd
248.075226, found 248.073976.
3-(2-Phenylethoxy)-5-(1-piperidyl)thiophene-2-carboxamide
(28). Ethyl 3-(2-phenylethoxy)-5-(1-piperidyl)thiophene-2-carboxy-
late (60 mg, 0.17 mmol) was dissolved in anhydrous THF (2 mL)
and placed under N2. LiNH2 (38 mg, 1.67 mmol) was added in one
portion, and the reaction was stirred for 48 h. The solvent was
evaporated and acidiﬁed (pH 2) with the minimum amount of 2 M
HCl. This was then extracted 3× with DCM and passed through a
hydrophobic frit, and the organics were concentrated in vacuo.
Puriﬁcation by column chromatography eluting with 0−100% EtOAc
in hexane aﬀorded a white solid (55 mg, 51%).1H NMR (400 MHz,
CDCl3) δ 7.37−7.33 (m, 2H), 7.30−7.26 (m, 3H), 5.75 (s, 1H), 4.34
(t, J = 7.03 Hz, 2H), 3.22 (m, 4H), 3.13 (t, J = 7.2 Hz, 2H), 1.73−
1.67 (m, 4H), 1.65−1.60 (m, 2H). HRMS (ES + ve), C18H23N2O2S
[M + H]+: calcd 331.1475, found 331.1466.
General Procedure E. L-Proline carboxamide (1 equiv), K2CO3
(4 equiv), L-Proline (0.38 equiv), and CuI (0.16 equiv) were added to
a microwave vial and sealed, purged with nitrogen (×3), and then
morpholin-3-one (1.7 equiv) and then anhydrous DMSO (2 mL)
were added. The vial was purged again with nitrogen (×3) and then
heated in the microwave reactor at 100 °C for 4 h. The reaction
mixture was partitioned between water (8 mL/mmol) and DCM (16
mL/mmol), and the aqueous layer was extracted with further DCM
(16 mL/mmol). The combined DCM extracts were evaporated in
vacuo, and the residue was puriﬁed by mass-directed HPLC 5−95%
MeCN acidic to aﬀord the desired product.
5-(3-Oxomorpholino)-3-phenethoxythiophene-2-carboxamide
(29). Prepared using general procedure E starting from 13 (90 mg,
0.24 mmol) and morpholin-3-one (41 mg, 0.41 mmol), colorless solid
(8 mg, 8%). 1H NMR (CDCl3, 400 MHz) δ 7.37 (dd, 2H, J = 7.2, 7.2
Hz), 7.28 (s, 3H), 6.58 (s, 1H), 4.42−4.38 (m, 4H), 4.09 (t, 2H, J =
5.1 Hz), 3.84 (t, 2H, J = 5.2 Hz), 3.16 (t, 2H, J = 6.8 Hz). HRMS (ES
+ ve), C17H18N2O4S [M + H]
+: calcd 347.1060, found 347.1044
5-(2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-methyl-3-phene-
thoxythiophene-2-carboxamide (30). Prepared using general
procedure E starting from 13 (70 mg, 0.18 mmol) and 2-oxa-5-
azabicyclo[2.2.1]heptane hydrochloride (41 mg, 0.30 mmol), color-
less solid (6 mg, 7%). 1H NMR (MeOD, 500 MHz,) δ 7.36−7.28 (m,
4H), 7.26−7.22 (m, 1H), 5.86 (s, 1H), 4.66 (s, 1H), 4.43−4.39 (m,
2H), 4.34 (s, 1H), 3.87 (d, 1H, J = 7.8 Hz), 3.79 (dd, 1H, J = 1.2, 7.6
Hz), 3.46 (dd, 1H, J = 1.4, 9.5 Hz), 3.13−3.07 (m, 3H), 2.67 (d, 3H, J
= 4.4 Hz), 2.03−1.93 (m, 2H). HRMS (ES + ve), C19H22N2O3S [M +
H]+: calcd 359.1424, found 359.1435.
5-(3-Methylmorpholino)-3-phenethoxythiophene-2-carboxa-
mide (31). Prepared using general procedure E starting from 13 (100
mg, 0.26 mmol) and 3-methylmorpholine (165 mg, 0.45 mmol),
colorless solid (10 mg, 14%). 1HNMR (CDCl3, 500 MHz,) δ 7.38−
7.34 (m, 3H), 7.29 (s, 2H), 5.74 (s, 1H), 4.35 (t, 2H, J = 6.9 Hz),
3.98 (dd, 1H, J = 3.7, 11.4 Hz), 3.80−3.74 (m, 2H), 3.69−3.60 (m,
2H), 3.29−3.23 (m, 1H), 3.16−3.12 (m, 3H), 1.29 (d, 3H, J = 6.6
Hz). HRMS (ES + ve), C18H22N2O3S [M + H]
+: calcd 347.1424,
found 347.1431.
5-[2-Methoxyethyl(methyl)amino]-3-(2-phenylethoxy)-
thiophene-2-carboxamide (32). Prepared using general procedure E
starting from 13 (80 mg, 0.21 mmol) and 2-methoxy-N-methyl-
ethanamine (29 mg, 0.32 mmol), pale orange solid (15 mg, 19%). 1H
NMR (500 MHz, CDCl3) δ 7.35−7.31 (m, 2H), 7.25−7.24 (m, 3H),
6.42 (br.s, 1H), 5.55 (s, 1H), 5.09 (br.s, 1H), 4.33 (t, J = 6.8 Hz, 2H),
3.57 (t, J = 5.5 Hz, 2H), 3.45 (t, J = 5.4 Hz, 2H), 3.34 (s, 3H), 3.11 (t,
J = 6.8 Hz, 2H), 3.01 (s, 3H). HRMS (ES + ve), C17H23N2O3S [M +
H]+: calcd 335.1424, found 335.1423.
Methyl 5-(Benzimidazol-1-yl)-3-hydroxy-thiophene-2-carboxy-
late (33a). Benzimidazole (67 mg, 0.57 mmol) was dissolved in
DCM (5 mL), methyl 2-chloro-3-oxo-thiophene-2-carboxylate (100
mg, 0.52 mmol) was added followed by potassium hydrogen
carbonate (52 mg, 0.52 mmol), and the mixture was stirred for 4 h,
partitioned between DCM/H2O and the organic layer passed through
a hydrophobic frit, and concentrated in vacuo. The precipitate that
formed was recrystallized from MeOH to aﬀord a colorless solid (125
mg, 88%). 1H NMR (300 MHz, MeOD) δ 8.46 (s, 1H), 7.86−7.76
(m, 2H), 7.48−7.38 (m, 2H), 6.82 (s, 1H), 3.83 (s, 3H). LC-MS m/z
275 [M + H].
5-(Benzimidazol-1-yl)-3-(2-phenylethoxy)thiophene-2-carboxa-
mide (33). To a cooled solution of 33a (75 mg, 0.20 mmol) in DCM
(1 mL) was added oxalyl chloride (0.019 mL, 0.22 mmol) and 1 drop
of DMF. The reaction was allowed to warm to rt, and after 1 h
ammonium hydroxide (33% aqueous, 0.5 mL) was added. The
reaction was left at rt for 36 h. The volatiles were removed in vacuo,
and the residue was partitioned between brine and EtOAc. The
organics were separated, dried (Na2SO4), ﬁltered, and concentrated in
vacuo. The residue was puriﬁed by prep HPLC (Gilson, ammonia, 5−
95% MeCN) to aﬀord a white solid (20 mg, 25%). 1H NMR (DMSO,
500 MHz) δ 8.59 (s, 1H), 7.79 (d, 1H, J = 8.0 Hz), 7.75 (d, 1H, J =
8.0 Hz), 7.58 (s, 1H), 7.54 (s, 1H), 7.39−7.36 (m, 1H), 7.34−7.27
(m, 6H), 7.23−7.18 (m, 1H), 6.71 (s, 1H), 4.48 (t, 2H, J = 6.7 Hz),
3.11 (t, 2H, J = 6.7 Hz). HRMS (ES + ve), C20H17N3O2S [M + H]
+:
calcd 364.1114, found 364.1098.
3-(2-Phenylethoxy)-5-(triazol-2-yl)thiophene-2-carboxamide
(34). 13 (250 mg, 0.67 mmol), CuI (13 mg, 0.067 mmol), and K2CO3
(204 mg, 1.47 mmol) were added to a vial, and the vial was sealed and
purged with nitrogen. Then DMF (3 mL), 1H-triazole (69 mg, 1.0
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mmol), and N,N′-dimethyl-1,2-cyclohexanediamine (29 mg, 0.20
mmol) were added, and the reaction was heated at 110 °C for 16 h
and diluted with DCM. H2O was added, and the organic solvent was
removed in vacuo. Puriﬁcation by prep HPLC, white solid (12 mg,
6%) . 1H NMR (300 MHz, acetone) δ 8.03 (s, 2H), 7.48 (s, 1H),
7.45−7.32 (m, 4H), 7.31−7.24 (m, 1H), 6.80−6.77 (m, 1H), 6.66−
6.65 (m, 1H), 4.66 (dd, J = 6.6, 6.6 Hz, 2H), 3.25 (dd, J = 6.6, 6.6 Hz,
2H),HRMS (ES + ve), C15H14N4O2S [M + H]
+: calcd 315.0910,
found 315.0906.
3-(2-Phenylethoxy)-5-(4-pyridyl)thiophene-2-carboxamide (35).
To a sealed vial containing 13 (130 mg, 0.35 mmol), Cs2CO3 (340
mg, 1.05 mmol), Pd(PPh3)4 (40 mg, 0.035 mmol), and 4-
pyridinylboronic acid (66 mg, 0.49 mmol) under N2 was added
DMF (3 mL). The reaction was then stirred at 80 °C for 16 h, diluted
with EtOAc, and ﬁltered through a silica pad, and the ﬁltrate was
concentrated in vacuo. Puriﬁcation by ﬂash chromatography eluting
with 0−100% EtOAc in heptanes aﬀorded a yellow solid (53 mg,
45%). 1H NMR (400 MHz, CDCl3) δ 8.68−8.65 (m, 2H), 7.48−7.46
(m, 2H), 7.46−7.35 (m, 2H), 7.33−7.29 (m, 3H), 7.23 (s, 1H), 6.78
(br.s, 1H), 5.36 (br.s, 1H), 4.51 (t, J = 6.6 Hz, 2H), 3.20 (t, J = 6.6
Hz, 2H). HRMS (ES + ve), C18H17N2O2S [M + H]
+: calcd 325.1005,
found 325.1008.
3-[2-(4-Methoxyphenyl)ethoxy]-5-morpholinothiophene-2-car-
boxamide (36). Prepared using general procedure D starting from 7
(250 mg, 1.09 mmol) and 2-(4-methoxyphenyl)ethanol (183 mg, 1.20
mmol), oﬀ-white solid (15 mg, 3%). 1H NMR (DMSO, 500 MHz) δ
7.24−7.21 (m, 2H), 6.95 (br s, 1H), 6.89−6.86 (m, 2H), 6.38 (br s,
1H), 6.22 (s, 1H), 4.29 (t, 2H, J = 6.8 Hz), 3.74 (s, 3H), 3.71 (t, 4H, J
= 4.9 Hz), 3.15−3.12 (m, 4H), 3.00 (t, 2H, J = 6.8 Hz). HRMS (ES +
ve), C18H22N2O4S [M + H]
+: calcd 363.1373, found 363.1376.
5-Morpholino-3-[2-[4-(triﬂuoromethoxy)phenyl]ethoxy]-
thiophene-2-carboxamide (37). Prepared using general procedure D
starting from 7 (300 mg, 1.31 mmol) and 2-[4-(triﬂuoromethoxy)-
phenyl]ethanol (298 mg, 1.44 mmol), colorless solid (96 mg, 17%).
1H NMR (DMSO, 500 MHz) δ 7.46 (d, 2H, J = 8.7 Hz), 7.31 (d, 2H,
J = 7.9 Hz), 6.95 (s, 1H), 6.39 (s, 1H), 6.24 (s, 1H), 4.35 (t, 2H, J =
6.8 Hz), 3.71 (m, 4H), 3.16−3.10 (m, 6H). HRMS (ES + ve),
C18H19N2O4F3S [M + H]
+: calcd 417.1094, found 417.1091.
3-[2-(2-Methoxyphenyl)ethoxy]-5-morpholinothiophene-2-car-
boxamide (38). Prepared using general procedure D starting from 7
(300 mg, 1.31 mmol) and 2-(2-ﬂuorophenyl)ethanol (202 mg, 1.44
mmol), colorless solid (105 mg, 22%). 1H NMR (DMSO, 500 MHz)
δ 7.44−7.39 (m, 1H), 7.34−7.28 (m, 1H), 7.20−7.15 (m, 2H), 6.98
(br s, 1H), 6.40 (br s, 1H), 6.23 (s, 1H), 4.33 (t, 2H, J = 6.5 Hz), 3.71
(m, 4H), 3.15−3.10 (m, 6H). HRMS (ES + ve), C17H20FN2O3S [M +
H]+: calcd 351.1173, found 351.1204.
3-[2-(3-Fluorophenyl)ethoxy]-5-morpholinothiophene-2-carbox-
amide (39). Prepared using general procedure D starting from 2-(3-
ﬂuorophenyl)ethanol (337 mg, 2.40 mmol) and 7 (500 mg, 2.19
mmol), colorless solid (49 mg, 6%). 1H NMR (DMSO, 500 MHz)
7.36 (m, 1H), 7.21−7.15 (m, 2H), 7.09−7.04 (m, 1H), 6.96 (s, 1H),
6.37 (s, 1H), 6.25 (s, 1H), 4.36 (t, 2H, J = 6.8 Hz), 3.71(m, 4H),
3.16−3.08 (m, 6H). HRMS (ES + ve), C17H20FN2O3S [M + H]+:
calcd 351.1173, found 351.1177.
3-(3-(4-Fluorophenyl)propyl)-5-morpholinothiophene-2-carbox-
amide (40). Prepared using general procedure D starting from 7 (100
mg, 0.44 mmol)and 2-(4-ﬂuorophenyl)ethanol (67.5 mg, 0.48 mmol),
colorless solid (20 mg, 13%). 1H NMR (500 MHz, CDCl3) δ 7.13
(dd, J = 5.4, 8.5 Hz, 2H), 6.95 (dd, J = 8.6, 8.5 Hz, 2H), 5.72 (s, 1H),
4.24 (dd, J = 6.7, 6.7 Hz, 2H), 3.76−3.73 (m, 4H), 3.12−3.09 (m,
4H), 3.01 (dd, J = 6.6, 6.6 Hz, 2H). LCMS (acidic, 20−90% MeCN)
m/z 351 (100) rt 2.5. HRMS (ES + ve), C17H20FN2O3S [M + H]
+:
calcd 351.1173, found 351.1180.
3-[2-(3-Methoxyphenyl)ethoxy]-5-morpholinothiophene-2-car-
boxamide (41). Prepared using general procedure D starting from 7
(250 mg, 1.09 mmol) and 2-(3-methoxyphenyl)ethanol (183 mg, 1.20
mmol), colorless solid (5.8 mg, 1%). 1H NMR (CDCl3, 500 MHz) δ
7.18−7.16 (s, 1H), 6.78−6.71 (m, 3H), 5.73 (s, 1H), 4.25 (t, 2H, J =
6.7 Hz), 3.76−3.73 (m, 4H), 3.73 (s, 3H), 3.12−3.09 (m, 4H), 3.01
(t, 2H, J = 6.7 Hz). HRMS (ES + ve), C18H23N2O4S [M + H]
+: calcd
363.1373, found 363.1373.
3-[2-(2-Methoxyphenyl)ethoxy]-5-morpholinothiophene-2-car-
boxamide (42). Prepared using general procedure D starting from 7
(250 mg, 1.09 mmol) and 2-(2-methoxyphenyl)ethanol (183 mg, 1.20
mmol), colorless solid (1.8 mg, 0.4%). 1H NMR (CDCl3, 500 MHz)
δ 7.27 (dd, 1H, J = 1.8, 8.1 Hz), 7.20 (dd, 1H, J = 1.7, 7.5 Hz), 6.96−
6.90 (m, 2H), 5.86 (br s, 1H), 4.33 (t, 2H, J = 6.8 Hz), 3.86 (s, 3H),
3.83 (m, 4H), 3.22−3.19 (m, 4H), 3.17 (t, 2H, J = 6.6 Hz). LC-MS
m/z 363 [M + H].
5-Morpholino-3-[2-(4-pyridyl)ethoxy]thiophene-2-carboxamide
(43). Prepared using general procedure D starting from 7 (100 mg,
0.43 mmol) and 2-(4-pyridyl)ethanol (59 mg, 0.48 mmol), oﬀ-white
solid (4.3 mg, 3%). 1H NMR (CDCl3, 500 MHz) δ 8.47−8.45 (m,
2H), 7.09−7.07 (m, 2H), 4.27 (t, 2H, J = 6.5 Hz), 3.73−3.70 (m,
4H), 3.09−3.07 (m, 4H), 3.01 (t, 2H, J = 6.6 Hz). HRMS (ES + ve),
C16H20N3O3S [M + H]
+: calcd 334.1220, found 334.1233.
3-[2-(4-Cyanophenyl)ethoxy]-5-morpholino-thiophene-2-car-
boxamid (44). Prepared using general procedure D starting from 4-
(2-hydroxyethyl)benzonitrile (212 mg, 1.4 mmol) 7 (300 mg, 1.3
mmol), colorless solid (82 mg, 17%). 1H NMR (DMSO, 500 MHz) δ
7.79−7.78 (m, 2H), 7.55−7.53 (m, 2H), 6.94 (s, 1H), 6.28 (s, 1H)
6.24 (s, 1H), 4.39 (t, 2H, J = 6.6 Hz), 3.71 (m, 4H), 3.18 (t, 2H, J =
6.6 Hz), 3.15−3.12 (m, 4H). HRMS (ES + ve), C18H19N3O3S [M +
H]+: calcd 358.1220, found 358.1218.
5-Morpholino-3-((tetrahydrofuran-2-yl)methoxy)thiophene-2-
carboxamide (45). Prepared using general procedure D starting from
7 (250 mg, 1.1 mmol) and tetrahydrofuran-2-ylmethanol (123 mg, 1.2
mmol), colorless solid (83 mg, 24%). 1H NMR (500 MHz, CDCl3) δ
6.82−6.82 (m, 1H), 5.82 (s, 1H), 5.43−5.43 (m, 1H), 4.09−4.08 (m,
2H), 4.00−3.95 (m, 1H), 3.88−3.76 (m, 6H), 3.23−3.20 (m, 5H),
2.79−2.72 (m, 1H), 2.21−2.13 (m, 1H), 1.83−1.76 (m, 1H). HRMS
(ES + ve), C14H20N2O4S [M + H]
+: calcd 313.1217, found 313.1218.
3-((3-Methyloxetan-3-yl)methoxy)-5-morpholinothiophene-2-
carboxamide (46). Prepared using general procedure D starting from
7 (250 mg, 1.1 mmol) and (3-methyloxetan-3-yl)methanol (123 mg,
1.2 mmol), colorless solid (129 mg, 37%). 1H NMR (500 MHz,
CDCl3) δ 7.08 (s, 1H), 5.87 (s, 1H), 5.28 (s, 1H), 4.68 (d, J = 6.1 Hz,
2H), 4.59 (d, J = 6.1 Hz, 2H), 4.12 (s, 2H), 3.87−3.85 (m, 4H),
3.25−3.22 (m, 4H), 1.39 (s, 3H). HRMS (ES + ve), C14H21N2O4S
(M+H)+: calcd 313.1217, found 313.1215.
5-Morpholino-3-(2-morpholinoethoxy)thiophene-2-carboxa-
mide (47). Prepared using general procedure D starting from 7 (250
mg, 1.1 mmol) and 2-morpholinoethanol (158 mg, 1.2 mmol), light
pink solid (38 mg, 10%). 1H NMR (CDCl3, 500 MHz) δ 5.74 (s,
1H), 4.11 (t, 2H, J = 5.6 Hz), 3.74 (m, 4H), 3.62 (m, 4H), 3.11 (m,
4H), 2.67 (t, 2H, J = 5.5 Hz), 2.45 (m, 4H). HRMS (ES + ve),
C15H23N3O4S [M + H]
+: calcd 342.1482, found 342.1497.
3-Benzyloxy-5-morpholinothiophene-2-carboxamide (48). Pre-
pared using general procedure D starting from 7 (250 mg, 1.1 mmol)
and phenylmethanol (130 mg, 1.2 mmol), oﬀ-white solid (3.4 mg,
0.9%). 1H NMR (CDCl3, 500 MHz,) δ 7.45−7.40 (m, 5H), 5.90 (s,
1H), 5.18 (s, 2H), 3.86−3.84 (m, 4H), 3.23−3.20 (m, 4H). HRMS
(ES + ve), C16H18N2O3S [M + H]
+: calcd 319.1111, found 319.1118.
Methyl 3-(3-Phenylpropyl)thiophene-2-carboxylate (49a). Meth-
yl 3-bromothiophene-2-carboxylate (600 mg, 2.7 mmol), 4,4,5,5-
tetramethyl-2-[(E)-3-phenylprop-1-enyl]-1,3,2-dioxaborolane (928
mg, 3.8 mmol), Cs2CO3 (2652 mg, 8.1 mmol), Pd(OAc)2 (61 mg,
0.27 mmol), triphenylphosphine (285 mg, 1.1 mmol), and THF
under N2 were heated at 80 °C for 16 h. The reaction was diluted
with DCM, and H2O was added. The organic layer was separated with
a hydrophobic frit, and the solvent was evaporated to aﬀord a pale
brown crude product. The crude product was dissolved in EtOH (10
mL), and then Pd/C (289 mg, 0.27 mmol) was added. The reaction
mixture was stirred at rt under H2 until complete reduction of the
double bond was observed by LCMS. The reaction was ﬁltered
through a Celite pad and the solvent evaporated. The resulting crude
material was further puriﬁed by ﬂash chromatography eluting with 0−
30% EtOAc in heptanes to aﬀord a colorless oil (640 mg, 91%). 1H
NMR (400 MHz, CDCl3) δ 7.32 (d, J = 4.6 Hz, 1H), 7.24−7.17 (m,
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2H), 7.14−7.09 (m, 3H), 6.88 (d, J = 4.8 Hz, 1H), 3.77 (s, 3H), 3.00
(t, J = 7.7 Hz, 2H), 2.61 (t, J = 7.7 Hz, 2H), 1.94−1.85 (m, 2H). LC-
MS m/z 261 [M + H].
Methyl 5-Iodo-3-(3-phenylpropyl)thiophene-2-carboxylate
(49b). Prepared using general procedure A starting from 49a (640
mg, 2.5 mmol), pale yellow solid (791 mg, 66%). 1H NMR (500
MHz, CDCl3) δ 7.33−7.28 (m, 3H), 7.22−7.18 (m, 2H), 7.12 (s,
1H), 3.84 (s, 3H), 3.04 (t, J = 7.9 Hz, 2H), 2.70 (t, J = 7.8 Hz, 2H),
1.99−1.91 (m, 2H). LCMS m/z 387 [M+H, low intensity].
5-Iodo-3-(3-phenylpropyl)thiophene-2-carboxamide (49c). Pre-
pared using general procedure B starting from 49b (300 mg, 0.78
mmol), oﬀ-white solid (115 mg, 35%). 1H NMR (400 MHz, CDCl3)
δ 7.34−7.28 (m, 2H), 7.22−7.19 (m, 3H), 7.12 (s, 1H), 5.41−5.41
(br.s, 2H), 2.95 (t, J = 7.7 Hz, 2H), 2.70 (t, J = 7.4 Hz, 2H), 2.01−
1.94 (m, 2H). LC-MS m/z 372 [M + H].
5-Morpholino-3-(3-phenylpropyl)thiophene-2-carboxamide
(49). Prepared using general procedure E starting from 49c (120 mg,
0.32 mmol) and morpholine (48 mg, 0.55 mmol), oﬀ-white solid (39
mg, 36%). 1H NMR (500 MHz, CDCl3) δ 7.33−7.29 (m, 2H), 7.24−
7.21 (m, 3H), 5.95 (s, 1H), 5.25 (br.s, 2H), 3.86−3.83 (m, 4H),
3.21−3.18 (m, 4H), 2.90 (t, J = 7.9 Hz, 2H), 2.73 (t, J = 7.6 Hz, 2H),
2.03−1.96 (m, 2H). HRMS (ES + ve), C18H23N2O2S [M + H]+: calcd
331.1475, found 331.1476.
Methyl 3-Phenacyloxythiophene-2-carboxylate (50a). To a
solution of methyl 3-hydroxythiophene-2-carboxylate (1000 mg, 6.3
mmol) in DMF (15 mL) were added 2-bromo-1-phenyl-ethanone
(1510 mg, 7.6 mmol) and K2CO3 (1311 mg, 9.5 mmol). The
resulting mixture was heated at 60 °C for 16 h. Then the reaction
mixture was cooled to rt, diluted with DCM, and ﬁltered to remove
the base. Then the solvent was evaporated to dryness. The resulting
crude was further puriﬁed by ﬂash chromatography eluting with 0−
100% EtOAc in heptanes to aﬀord the desired product (1265 mg,
72%) as an orange solid. 1H NMR (400 MHz, CDCl3) δ 8.05−8.01
(m, 2H), 7.64 (t, J = 7.3 Hz, 1H), 7.52 (t, J = 7.4 Hz, 2H), 7.38 (d, J
= 5.0 Hz, 1H), 6.76 (d, J = 5.0 Hz, 1H), 5.47 (s, 2H), 3.88 (s, 3H).
LC-MS m/z 299 [M + Na].
Methyl 3-(2,2-Diﬂuoro-2-phenylethoxy)thiophene-2-carboxylate
(50b). To a solution of 50a (400 mg, 1.5 mmol) in DCM (10 mL)
was added DAST (817 mg, 5.1 mmol). The reaction mixture was
stirred at 60 °C for 16 h. The solvent was removed under vacuum,
and the crude was puriﬁed by ﬂash chromatography eluting with 0−
70% EtOAc in heptanes to aﬀord the desired product (376 mg, 81%)
as a yellow oil. 1H NMR (500 MHz, CDCl3) 7.68−7.65 (2H, m),
7.50−7.47 (3H, m), 7.40 (1H, d, J = 5.5 Hz), 6.78 (1H, d, J = 5.5
Hz), 4.54 (2H, t, J = 11.9 Hz), 3.85 (3H, s). LC-MS m/z 321 [M +
Na].
Methyl 3-(2,2-Diﬂuoro-2-phenylethoxy)-5-iodo-thiophene-2-car-
boxylate (50c). Prepared using general procedure A starting from 50b
(376 mg, 1.3 mmol), pale yellow solid (468 mg, 77%). 1H NMR (400
MHz, CDCl3) δ 7.65−7.62 (m, 2H), 7.51−7.47 (m, 3H), 6.94 (s,
1H), 4.50 (t, J = 11.9 Hz, 2H), 3.83 (s, 3H). LC-MS m/z 425 [M +
H].
3-(2,2-Diﬂuoro-2-phenylethoxy)-5-iodothiophene-2-carboxa-
mide (50d). Prepared using general procedure starting from 50c (467
mg, 1.1 mmol), oﬀ-white solid (233 mg, 46%). 1H NMR (500 MHz,
CDCl3) δ 7.58−7.50 (m, 5H), 6.98 (s, 1H), 6.60 (br.s, 1H), 5.35
(br.s, 1H), 4.51 (t, J = 12.4 Hz, 2H). LC-MS m/z 410 [M + H].
3-(2,2-Diﬂuoro-2-phenylethoxy)-5-morpholinothiophene-2-car-
boxamide (50). To a microwave vial under a N2 atmosphere and
precharged with 50d (233 mg, 0.57 mmol), CuI (22 mg, 0.11 mmol),
L-Proline (26 mg, 0.23 mmol), and K2CO3 (314 mg, 2.27 mmol) was
added morpholine (84 mg, 0.97 mmol) followed by DMSO (3.5 mL)
and water (0.10 mL). The vial was sealed and stirred at 60 °C under
microwave conditions for 3 h. The reaction was diluted with DCM,
and H2O was added. The organics were separated with a hydrophobic
frit and concentrated to dryness, and the crude was puriﬁed by ﬂash
chromatography 0−100% EtOAc in heptanes to aﬀord an oﬀ-white
solid (69 mg, 32%). 1H NMR (500 MHz, CDCl3) δ 7.59−7.56 (m,
2H), 7.54−7.49 (m, 3H), 6.42 (br.s, 1H), 5.75 (s, 1H), 5.17 (br.s,
1H), 4.49 (t, J = 12.3 Hz, 2H), 3.85−3.82 (m, 4H), 3.20−3.18 (m,
4H). HRMS (ES + ve), C17H18N2O3F2S [M + H]
+: calcd 367.1076,
found 369.1079.
3-(2-Hydroxy-2-phenylethoxy)-5-morpholinothiophene-2-car-
boxamine (51). A solution of 7 (200 mg, 0.88 mmol) in DMF (2.5
mL) and K2CO3 (242 mg, 1.75 mmol) was stirred for 5 min; then 2-
phenyloxirane (158 mg, 1.31 mmol) was added. The vial was sealed,
and the reaction was heated up to 70 °C overnight. LCMS showed
SM consumed and formation of desired product as the main product.
The reaction was diluted with DCM and ﬁltered to remove the
inorganic base, the solvent removed, and the crude puriﬁed by column
chromatography eluting with 0−5% MeOH in DCM. The mixture
was then puriﬁed by prep HPLC (basic) to an orange solid (12 mg,
3.9% yield). 1H NMR (500 MHz, CDCl3) δ 7.47−7.38 (m, 5H), 5.82
(s, 1H), 5.16−5.12 (m, 1H), 4.27−4.25 (m, 2H), 3.83 (t, J = 5.0 Hz,
4H), 3.19 (t, J = 5.0 Hz, 4H), 2.62 (d, J = 3.2 Hz, 1H). LC-MS m/z
349 [M + H].
5-Morpholino-3-tetralin-1-yloxy-thiophene-2-carboxamide (52).
Prepared using general procedure D starting from 7 (250 mg, 1.1
mmol) and tetralin-1-ol (178 mg, 1.2 mmol), oﬀ-white solid (14 mg,
3%). 1H NMR (DMSO, 500 MHz) δ 7.35−7.33 (m, 1H), 7.29−7.26
(m, 1H), 7.24−7.17 (m, 2H), 6.93 (s, 1H), 6.49 (s, 1H), 6.36 (s, 1H)
5.56 (dd, 1H, J = 4.5, 4.5 Hz), 3.74 (m, 4H), 3.19 (m, 4H), 2.88−2.82
(m, 1H), 2.78−2.70 (m, 1H), 2.08−1.98 (m, 2H), 1.87−1.79 (m,
2H). HRMS (ES + ve), C19H22N2O3S [M + H]
+: calcd 359.1424,
found 359.1419.
3-Indan-1-yloxy-5-morpholinothiophene-2-carboxamide (53).
Prepared using general procedure D starting from indan-1-ol (176
mg, 1.31 mmol) and 7 (300 mg, 1.31 mmol), light yellow solid (37
mg, 8%). 1H NMR (500 MHz, DMSO) δ 7.52 (m, 2H), 7.21−7.08
(m, 4H), 7.17−7.13 (m, 2H), 5.27 (s, 1H), 4.29 (t, 1H, J = 8.0 Hz),
3.67−3.62 (m, 4H), 3.44 (m, 4H), 2.92−2.85 (m, 1H), 2.81−2.74
(m, 1H), 2.06−1.99 (m, 1H), 1.61 (m, 1H). HRMS (ES + ve),
C18H21N2O3S [M + H]
+: calcd 345.1268, found 345.1267.
4-Morpholino-2-phenethoxybenzamide (54). Methyl 2-hydroxy-
4-morpholino-benzoate (400 mg, 1.69 mmol) was dissolved in MeCN
(2 mL), Cs2CO3 (549 mg, 1.69 mmol) and 2-bromoethylbenzene
(343 mg, 1.8 mmol) were added, and the reaction was stirred at rt for
16 h. The inorganics were ﬁltered oﬀ, and the excess solvent was
removed in vacuo. The crude residue was columned, eluting with 0−
100% EtOAC in heptane. The desired product was isolated and
reacted on without further puriﬁcation with LiNH2 (37 mg, 1.7
mmol) in THF (2 mL) at rt for 16 h. The reaction mixture was
poured over ice and extracted into EtOAC, excess solvent was
removed in vacuo, and the crude residue was puriﬁed by column
chromatography eluting with 0−10% DCM/MeOH in DCM to aﬀord
the desired product as a colorless solid (6 mg, 1%). 1H NMR (500
MHz, CDCl3) δ 8.09 (d, J = 8.8 Hz, 1H), 7.39−7.35 (m, 2H), 7.32−
7.29 (m, 3H), 6.58 (dd, J = 2.3, 8.9 Hz, 1H), 6.38 (d, J = 2.2 Hz, 1H),
5.33 (s, 2H), 4.39 (t, J = 6.8 Hz, 2H), 3.87 (t, J = 4.9 Hz, 4H), 3.28−
3.20 (m, 6H). HRMS (ES + ve), C19H23N2O3 [M + H]
+: calcd
327.1700, found 327.1703.
Methyl 5-Bromo-2-(2-phenylethoxy)benzoate (55a). Prepared
using general procedure D starting from methyl 5-bromo-2-hydroxy-
benzoate (0.50 g, 2.2 mmol) and 2-phenylethanol (0.29 g, 2.4 mmol),
colorless solid (0.46 g, 63%). 1H NMR (300 MHz, CDCl3) δ 7.91 (d,
J = 2.4 Hz, 1H), 7.53 (dd, J = 2.4, 8.9 Hz, 1H), 7.34 (s, 5H), 6.84 (d, J
= 8.9 Hz, 1H), 4.24 (t, J = 7.0 Hz, 2H), 3.91 (s, 3H), 3.17 (t, J = 7.0
Hz, 2H). LC-MS m/z 335, 337 [M+H, 1:1 Br characteristic isotopic
abundance ratio].
Methyl 5-Morpholino-2-(2-phenylethoxy)benzoate (55b). To a
sealed vial precharged with 55a (457 mg, 1.36 mmol), Pd(OAc)2
(15.4 mg, 0.068 mmol), BINAP (85 mg, 0.14 mmol), and Cs2CO3
(666 mg, 2.04 mmol) under N2 was added toluene (4 mL) and then
morpholine (154 mg, 1.77 mmol). The resulting mixture was then
heated to 100 °C for 16 h. The reaction was then diluted with EtOAc,
and the organics were washed with brine. The organics were then
separated and dried (MgSO4) before concentration to dryness. The
crude was puriﬁed by ﬂash column chromatography eluting with 0−
60% EtOAc in heptanes to aﬀord the desired product (263 mg, 56%)
as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.39−7.32 (m, 6H),
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7.04 (dd, J = 3.0, 9.0 Hz, 1H), 6.91 (d, J = 9.0 Hz, 1H), 4.21 (t, J =
7.1 Hz, 2H), 3.90−3.85 (m, 7H), 3.19−3.08 (m, 6H). LC-MS m/z
342.1 [M + H].
5-Morpholino-2-(2-phenylethoxy)benzamide (55). Prepared
using general procedure B starting from 55b (266 mg, 0.77 mmol),
pale yellow solid (77 mg, 29%). 1H NMR (300 MHz, CDCl3) δ 7.78
(d, J = 3.0 Hz, 1H), 7.49 (br.s, 1H), 7.32−7.30 (m, 5H), 7.04 (dd, J =
3.1, 8.9 Hz, 1H), 6.96 (d, J = 9.0 Hz, 1H), 5.43 (br.s, 1H), 4.37 (t, J =
6.6 Hz, 2H), 3.90−3.85 (m, 4H), 3.22−3.11 (m, 6H). HRMS (ES +
ve), C19H23N2O3 [M + H]
+: calcd 327.1703, found 327.1697.
5-Bromo-2-[2-(3-ﬂuorophenyl)ethoxy]benzoate (56a). Prepared
using general procedure D starting from methyl 5-bromo-2-hydroxy-
benzoate (1.5 g, 6.5 mmol) and 2-(3-ﬂuorophenyl)ethanol (1.0 g, 7.1
mmol), white solid (1.45 g, 63%). 1H NMR (500 MHz, CDCl3) δ
7.91 (d, J = 2.5 Hz, 1H), 7.53 (dd, J = 2.5, 8.8 Hz, 1H), 7.30−7.28
(m, 1H), 7.11−7.07 (m, 2H), 6.98−6.94 (m, 1H), 6.83 (d, J = 8.8 Hz,
1H), 4.23 (t, J = 6.6 Hz, 2H), 3.91 (s, 3H), 3.16 (t, J = 6.5 Hz, 2H).
LC-MS m/z 353, 355 [M+H, 1:1 Br characteristic isotopic abundance
ratio].
2-[2-(3-Fluorophenyl)ethoxy]-5-morpholino-benzoate (56b). To
a sealed vial precharged with 56a (400 mg, 1.1 mmol), Pd(OAc)2
(12.7 mg, 0.05 mmol), BINAP (71 mg, 0.1 mmol), and Cs2CO3 (554
mg, 1.7 mmol) under nitrogen atmosphere was added toluene (4 mL)
and then morpholine (128 mg, 1.5 mmol). The resulting mixture was
then heated to 100 °C for 16 h. The reaction was then diluted with
EtOAc, and the organics were washed with brine. The organics were
then separated and dried (MgSO4) before concentration in vacuo.
The crude was puriﬁed by ﬂash column chromatography eluting with
0−60% EtOAc in heptanes. The desired fractions were concentrated
to dryness in vacuo to obtain a yellow solid (184 mg, 45%). 1H NMR
(500 MHz, CDCl3) δ 7.37 (d, J = 3.0 Hz, 1H), 7.11−7.01 (m, 4H),
6.97−6.92 (m, 1H), 6.90 (d, J = 9.0 Hz, 1H), 4.21 (t, J = 6.6 Hz, 2H),
3.90 (s, 3H), 3.88−3.76 (m, 4H), 3.15−3.09 (m, 6H). LC-MS m/z
360.15 [M + H].
2-[2-(3-Fluorophenyl)ethoxy]-5-morpholino-benzamide (56).
Prepared using general procedure B starting from 56b (184 mg,
0.51 mmol), colorless solid (114 mg, 65%). 1H NMR (300 MHz,
CDCl3) δ 7.78 (d, J = 3.2 Hz, 1H), 7.47 (br.s, 1H), 7.37−7.30 (m,
1H), 7.10−6.93 (m, 5H), 5.55 (br.s, 1H), 4.36 (t, J = 6.6 Hz, 2H),
3.87−3.78 (m, 4H), 3.22−3.12 (m, 6H). HRMS (ES + ve),
C19H22FN2O3 [M + H]
+: calcd 363.1373, found 363.1373.
6-Morpholino-3-(2-phenylethoxy)pyridine-2-carboxamide (57).
Prepared using general procedure B starting from methyl 6-
morpholino-3-(2-phenylethoxy)pyridine-2-carboxylate colorless gum
(100 mg, 15%). 1H NMR (400 MHz, CDCl3) δ 7.35- 7.12 (m, 6H),
6.71 (d, J = 10.2 Hz, 1H), 5.66 (s, 1H), 4.16 (t, J = 6.9 Hz, 2H), 3.75
(m, 4H), 3.36 (m, 4H), 3.08 (t, J = 7.02 Hz, 2H). HRMS (ES + ve),
C18H23N2O2S [M + H]
+: calcd 328.1656, found 328.1654.
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■ ABBREVIATIONS USED
MOT, morpholino thiophenes; Qcrb, Cytochrome bc1
complex Cytochrome b subunit; TB, tuberculosis; HIV,
human immunodeﬁciency virus; MIC, minimum inhibitory
concentration; PFI, property forecast index; CYP, cytochrome
P450; hERG, human Ether-a-̀go-go-Related Gene; TPSA, total
polar surface area; DIAD, diisopropyl azodicarboxylate; LDA,
lithium diisopropylamide; Cli, intrinsic clearance; DCM,
dichloromethane; DMF, dimethylforamide; AUC, area under
curve; HPV, hepatic portal vein; PK, pharmacokinetic; ER,
extraction ration; MDCK, madin darby canine kidney; P-gp, P-
glycoprotein; HBD, hydrogen bond donor; HTSA, high
throughout solubility assay; FaSSIF, fasted state gastric ﬂuid;
CFU, colony forming unit; WT, wild type
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Fütterer, K.; Robbins, S. H.; Barnes, S. W.; Walker, J. R.; Jacobs, W.
R.; Schultz, P. G. Identification of a small molecule with activity
against drug-resistant and persistent tuberculosis. Proc. Natl. Acad. Sci.
U. S. A. 2013, 110 (27), E2510−E2517.
(20) Kang, S.; Kim, R. Y.; Seo, M. J.; Lee, S.; Kim, Y. M.; Seo, M.;
Seo, J. J.; Ko, Y.; Choi, I.; Jang, J.; Nam, J.; Park, S.; Kang, H.; Kim, H.
J.; Kim, J.; Ahn, S.; Pethe, K.; Nam, K.; No, Z.; Kim, J. Lead
Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides
Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-
Drug-Resistant Anti-tuberculosis Agent. J. Med. Chem. 2014, 57 (12),
5293−5305.
(21) Pethe, K.; Bifani, P.; Jang, J.; Kang, S.; Park, S.; Ahn, S.; Jiricek,
J.; Jung, J.; Jeon, H. K.; Cechetto, J.; Christophe, T.; Lee, H.; Kempf,
M.; Jackson, M.; Lenaerts, A. J.; Pham, H.; Jones, V.; Seo, M. J.; Kim,
Y. M.; Seo, M.; Seo, J. J.; Park, D.; Ko, Y.; Choi, I.; Kim, R.; Kim, S.
Y.; Lim, S.; Yim, S.-A.; Nam, J.; Kang, H.; Kwon, H.; Oh, C.-T.; Cho,
Y.; Jang, Y.; Kim, J.; Chua, A.; Tan, B. H.; Nanjundappa, M. B.; Rao,
S. P. S.; Barnes, W. S.; Wintjens, R.; Walker, J. R.; Alonso, S.; Lee, S.;
Kim, J.; Oh, S.; Oh, T.; Nehrbass, U.; Han, S.-J.; No, Z.; Lee, J.;
Brodin, P.; Cho, S.-N.; Nam, K.; Kim, J. Discovery of Q203, a potent
clinical candidate for the treatment of tuberculosis. Nat. Med. 2013,
19 (9), 1157−1160.
(22) Abrahams, K. A.; Cox, J. A. G.; Spivey, V. L.; Loman, N. J.;
Pallen, M. J.; Constantinidou, C.; Fernańdez, R.; Alemparte, C.;
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